WO2001094629A2 - Cancer gene determination and therapeutic screening using signature gene sets - Google Patents

Cancer gene determination and therapeutic screening using signature gene sets Download PDF

Info

Publication number
WO2001094629A2
WO2001094629A2 PCT/US2001/010838 US0110838W WO0194629A2 WO 2001094629 A2 WO2001094629 A2 WO 2001094629A2 US 0110838 W US0110838 W US 0110838W WO 0194629 A2 WO0194629 A2 WO 0194629A2
Authority
WO
WIPO (PCT)
Prior art keywords
gene
expression
cancer
genes
agent
Prior art date
Application number
PCT/US2001/010838
Other languages
French (fr)
Other versions
WO2001094629A3 (en
WO2001094629A8 (en
Inventor
Paul E. Young
Meena Augustus
Kenneth C. Carter
Reinhard Ebner
Greg Endress
Steve Horrigan
Daniel R. Soppet
Zoe Weaver
Original Assignee
Avalon Pharmaceuticals
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Avalon Pharmaceuticals filed Critical Avalon Pharmaceuticals
Priority to AU2001264559A priority Critical patent/AU2001264559A1/en
Priority to EP01938990A priority patent/EP1358349A2/en
Priority to JP2002502169A priority patent/JP2004509612A/en
Priority to CA002411601A priority patent/CA2411601A1/en
Publication of WO2001094629A2 publication Critical patent/WO2001094629A2/en
Publication of WO2001094629A8 publication Critical patent/WO2001094629A8/en
Publication of WO2001094629A3 publication Critical patent/WO2001094629A3/en
Priority to US10/843,641 priority patent/US20050064454A1/en

Links

Classifications

    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/5011Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing antineoplastic activity
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12QMEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12QMEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00Oligonucleotides characterized by their use
    • C12Q2600/136Screening for pharmacological compounds
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12QMEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00Oligonucleotides characterized by their use
    • C12Q2600/158Expression markers

Definitions

  • the present invention relates to methods of assaying potential anti- tumor agents based on their modulation of the expression of specified sets of genes and methods for diagnosing cancerous, or potentially cancerous, conditions as a result of the patterns of expression of such gene sets.
  • Screening assays for novel drugs are based on the response of model cell based systems in vitro to treatment with specific compounds.
  • Various measures of cellular response have been utilized, including the release of cytokines, alterations in cell surface markers, activation of specific enzymes, as well as alterations in ion flux and/or pH.
  • Some such screens rely on specific genes, such as oncogenes (or gene mutations).
  • characteristic sets of gene sequences whose expression, or non-expression, or change in expression, either an increase or decrease thereof, are indicative of the cancerous or non-cancerous status of a given cell. More particularly, such genes whose expression is changed in cancerous, as compared to non- cancerous cells, from a specific tissue (in particular, any of those disclosed herein) are genes that include one of the nucleotide sequences of SEQ ID NO: 1 - 8447, or sequences that are substantially identical to said sequences. Such a change in expression may be an increase or a decrease in expression or activity of the gene or gene sequences disclosed herein. It is another object of the present invention to provide methods of using such characteristic, or signature, gene sets as a basis for assaying the potential ability of selected chemical agents to modulate upward or downward the expression of said characteristic, or signature, gene sets.
  • the present invention relates to a process for determining a cancer initiating, facilitating or suppressing gene comprising the steps of contacting a cancerous cell with a cancer modulating agent and determining a change in expression of a gene selected from the group consisting of the gene sequences of SEQ ID NO: 1 - 8447 and thereby identifying said gene as being a cancer initiating or facilitating gene.
  • Said genes may, for example, be oncogenes, cancer facilitating or promoting genes, or cancer suppressor genes.
  • Said agents may increase or decrease gene expression.
  • the present invention also relates to a process for treating cancer comprising contacting a cancerous cell with an agent having activity against an expression product encoded by a gene sequence selected from the group consisting of SEQ ID NO: 1 - 8447, which process may be conducted either ex vivo or in vivo.
  • agents may comprise an antibody or other molecule or portion that is specific for said expression product.
  • the present invention further relates to process for determining a cancer initiating, facilitating or suppressing gene in a cancer cell comprising determining a change in expression of a gene sequence selected from the group consisting of the sequences of SEQ ID NO: 1 - 8447.
  • Such change in expression is especially a change to a difference in copy number and said difference, either an increase or decrease thereof, and wherein said change is monitored or otherwise determined as a change in messenger RNA formation.
  • Such change can be readily used to diagnose a cancerous condition, either in vivo or ex vivo.
  • the present invention still further relates to a process for treating cancer comprising inserting into a cancerous cell a gene construct comprising an anti-cancer gene operably linked to a promoter or enhancer element such that expression of said anti-cancer gene causes suppression of said cancer and wherein said promoter or enhancer element is a promoter or enhancer element modulating a gene sequence selected from the group consisting of the sequences of SEQ ID NO: 1 - 8447, wherein said gene may be a cancer suppressor gene, or where said gene encodes a polypeptide having anticancer activity, such as one with apoptotic activity.
  • the present invention relates to a process for determining functionally related genes comprising contacting one or more gene sequences selected from the group consisting of the sequences of SEQ ID NO: 1 - 8447 with an agent that modulates expression of more than one gene in such group and thereby determining a subset of genes of said group.
  • Said functionally related genes include genes modulating the same metabolic pathway or encoding functionally related polypeptides or where said expression is modulated by the same transcription activator or enhancer sequence.
  • the present invention also relates to a method for producing a product comprising identifying an agent according to the process of claim
  • said product is the data collected with respect to said agent as a result of said process and wherein said data is sufficient to convey the chemical structure and/or properties of said agent.
  • the present invention relates to methods of assaying potential antitumor agents based on their modulation of the expression of specified sets of genes and methods for diagnosing cancerous, or potentially cancerous, conditions as a result of the patterns of expression of such gene sets and for determining cancer-inducing or regulating genes, and gene sets, based on common expression or regulation of such genes, or gene sets.
  • model cellular systems using cell lines, primary cells, or tissue samples are maintained in growth medium and may be treated with compounds that may be at a single concentration or at a range of concentrations.
  • cellular RNAs are isolated from the treated cells, primary cells or tumors, which RNAs are indicative of expression of selected genes.
  • the cellular RNA is then divided and subjected to analysis that detects the presence and/or quantity of specific RNA transcripts, which transcripts may then be amplified for detection purposes using standard methodologies, such as, for example, reverse transcriptase polymerase chain reaction (RT-PCR), etc.
  • RT-PCR reverse transcriptase polymerase chain reaction
  • RNA transcripts are determined from these measurements and a metric derived for the type and degree of response of the sample to the treated compound compared to control samples.
  • characteristic, or signature sets of genes and gene sequences whose expression is, or can be, as a result of the methods of the present invention, linked to, or used to characterize, the cancerous, or non-cancerous, status of the cells, or tissues, to be tested.
  • the methods of the present invention identify novel anti-neoplastic agents based on their alteration of expression of small sets of characteristic, or indicator, or signature genes in specific model systems.
  • the methods of the invention may therefore be used with a variety of cell lines or with primary samples from tumors maintained in vitro under suitable culture conditions for varying periods of time, or in situ in suitable animal models.
  • certain genes have been identified that are expressed at levels in cancer cells that are different than the expression levels in non-cancer cells.
  • the identified genes are expressed at higher levels in cancer cells than in normal cells.
  • the identified genes are expressed at lower levels in cancer cells as compared to normal cells.
  • the present invention relates to process for screening for an anti-neoplastic agent comprising the steps of:
  • such change in expression may be an increase or a decrease in expression or activity. More particularly, the present invention relates to a process for screening for an anti-neoplastic agent comprising the steps of:
  • step (b) exposing a known cancerous cell to a chemical agent to be tested for antineoplastic activity; (b) allowing said chemical agent to modulate the activity of one or more genes present in said cell wherein said genes include or comprise one of the sequences selected from the group consisting of the sequences of SEQ ID NO: 1 - 8447, sequences substantially identical to said sequences, or the complements of any of the foregoing; (c) determining the expression of one or more genes of step (b);
  • said chemical agent to be tested modulates the expression of more than one said gene, especially where it modulates at least two said genes, more especially where at least 3, or at least 5 of said genes, or even 10 or more of said genes in said signature set, are modulated. In a preferred embodiment, all of said genes are modulated.
  • said gene modulation is downward modulation, so that, as a result of exposure to the chemical agent to be tested, one or more genes of the cancerous cell will be expressed at a lower level (or not expressed at all) when exposed to the agent as compared to the expression when not exposed to the agent.
  • a selected set of said genes are expressed in the reference cell but not expressed in the cell to be tested as a result of the exposure of the cell to be tested to the chemical agent.
  • said chemical agent causes the gene, or genes, of the tested cell to be expressed at a lower level than the same genes of the reference, this is indicative of downward modulation and indicates that the chemical agent to be tested has anti-neoplastic activity.
  • exposure of said cells to be tested to the chemical agent, especially one suspected of having anti-neoplastic activity may result in upward modulation of said genes of the cell to be tested.
  • Such upward modulation is interpreted as meaning that said genes are expressed where previously not expressed, or else are expressed in greater quantities when exposed to the agent as compared to non-exposure to the agent.
  • Such upward modulation may be taken as indicative of anti-neoplastic activity by the tested chemical agent(s) of the gene, or genes, so modulated results in lower neoplastic activity on the part of such cells, such as where increased expression of the gene, or genes, results in decreased growth and/or increased differentiation of said cells away from the cancerous state.
  • genes useful in the assay processes include, respectively, as a part thereof at least one of the sequences selected from the group consisting of the sequences of SEQ ID NO: 1 - 8447, or sequences substantially identical thereto. Such sequences also include sequences complementary to any of the sequences disclosed herein.
  • sequences at least 90% identical to a sequence selected from SEQ ID NO: 1 - 8447 preferably at least about 95% identical to such a sequence, more preferably at least about 98% identical to such sequence and most preferably 100% identical to such a sequence are specifically contemplated by all of the processes of the present invention.
  • sequences encoding the same proteins as any of these sequences, regardless of the percent identity of such sequences are also specifically contemplated by any of the methods of the present invention that rely on any or all of said sequences, regardless of how they are otherwise described or limited.
  • any such sequences are available for use in carrying out any of the methods disclosed according to the invention.
  • Such sequences also include any open reading frames, as defined herein, present within any of the sequences of SEQ ID NO: 1 - 8447.
  • percent identity when referring to a sequence, means that a sequence is compared to a claimed or described sequence after alignment of the sequence to be compared (the "Compared Sequence") with the described or claimed sequence (the "Reference Sequence”).
  • the Percent Identity is then determined according to the following formula:
  • C is the number of differences between the Reference Sequence and the Compared Sequence over the length of alignment between the Reference Sequence and the Compared Sequence wherein (i) each base or amino acid in the Reference Sequence that does not have a corresponding aligned base or amino acid in the Compared Sequence and (ii) each gap in the Reference Sequence and (iii) each aligned base or amino acid in the Reference Sequence that is different from an aligned base or amino acid in the Compared Sequence, constitutes a difference; and R is the number of bases or amino acids in the Reference Sequence over the length of the alignment with the Compared Sequence with any gap created in the Reference Sequence also being counted as a base or amino acid.
  • portion when used in relation to polypeptides, refer to a continuous sequence of residues, such as amino acid residues, which sequence forms a subset of a larger sequence.
  • residues such as amino acid residues
  • fragment when used in relation to polypeptides, refer to a continuous sequence of residues, such as amino acid residues, which sequence forms a subset of a larger sequence.
  • the oligopeptides resulting from such treatment would represent portions, segments or fragments of the starting polypeptide.
  • such terms refer to the products produced by treatment of said polynucleotides with any of the common endonucleases, or any stretch of polynucleotides that could be synthetically synthesized.
  • DNA segment refers to a DNA polymer, in the form of a separate fragment or as a component of a larger DNA construct, which has been derived from DNA isolated at least once in substantially pure form, i.e., free of contaminating endogenous materials and in a quantity or concentration enabling identification, manipulation, and recovery of the segment and its component nucleotide sequences by standard biochemical methods, for example, using a cloning vector.
  • segments are provided in the form of an open reading frame uninterrupted by internal nontranslated sequences, or introns, which are typically present in eukaryotic genes.
  • Sequences of non- translated DNA may be present downstream from the open reading frame, where the same do not interfere with manipulation or expression of the coding regions.
  • the term "coding region" refers to that portion of a gene which either naturally or normally codes for the expression product of that gene in its natural genomic environment, i.e., the region coding in vivo for the native expression product of the gene.
  • the coding region can be from a normal, mutated or altered gene, or can even be from a DNA sequence, or gene, wholly synthesized in the laboratory using methods well known to those of skill in the art of DNA synthesis.
  • nucleotide sequence refers to a heteropolymer of deoxyribonucleotides.
  • DNA segments encoding the proteins provided by this invention are assembled from cDNA fragments and short oligonucleotide linkers, or from a series of oligonucleotides, to provide a synthetic gene which is capable of being expressed in a recombinant transcriptional unit comprising regulatory elements derived from a microbial or viral operon.
  • expression product means that polypeptide or protein that is the natural translation product of the gene and any nucleic acid sequence coding equivalents resulting from genetic code degeneracy and thus coding for the same amino acid(s).
  • fragment when referring to a coding sequence, means a portion of DNA comprising less than the complete coding region whose expression product retains essentially the same biological function or activity as the expression product of the complete coding region.
  • primer means a short nucleic acid sequence that is paired with one strand of DNA and provides a free 3'-OH end at which a DNA polymerase starts synthesis of a deoxyribonucleotide chain.
  • promoter means a region of DNA involved in binding of RNA polymerase to initiate transcription.
  • enhancer refers to a region of DNA that, when present and active, has the effect of increasing expression of a different DNA sequence that is being expressed, thereby increasing the amount of expression product formed from said different DNA sequence.
  • ORF open reading frame
  • reference to a DNA sequence includes both single stranded and double stranded DNA.
  • specific sequence unless the context indicates otherwise, refers to the single strand DNA of such sequence, the duplex of such sequence with its complement (double stranded
  • relative antineoplastic activity may be ascertained by the extent to which a given chemical agent modulates the expression of genes present in a cancerous cell.
  • a first chemical agent that modulates the expression of a gene associated with the cancerous state i.e., a gene that includes one of the sequences disclosed herein and present in cancerous cells
  • a second chemical agent tested by the assays of the invention is thereby deemed to have higher, or more desirable, or more advantageous, anti-neoplastic activity than said second chemical agent.
  • first and second chemical agents modulate expression of more than one of said genes, but where the second modulates expression of, for example, five said genes, whereas the first modulates expression of only three of said genes, especially where the three form a subset of the five, then the second chemical agent is deemed a more potent anti-neoplastic agent than the first.
  • anti-neoplastic activity as determined using the assays of the present invention, may necessarily include combinations of the foregoing possibilities, which are in no way to be considered limiting.
  • the genes whose activity is to be determined with and without the presence of the compound to be evaluated for antitumor activity may be any one, or several, or any combination of the gene sequences disclosed herein as SEQ ID NO: 1 - 8447.
  • how the gene sequences are employed in such assays depends on the pattern of gene expression disclosed for the signature sets for the different organs and tissues. For example, a sequence that is expressed in cancerous cells but not in normal cells will identify a a potential anticancer agent by that agent's ability to decrease expression of the sequence, or sequences, in tumor cells.
  • sequences, or sequences, expressed in normal but not tumor cells will identify a potential antitumor agent by its ability to increase expression in the tumor cells.
  • sequences are expressed in both cancer and normal cells but are expressed at a higher level in one than in the other, and vice versa.
  • sequences, or signature gene sets are utilized to determine the cancerous state of a cell or use of an agent to treat a cancerous condition.
  • the present invention relates to a process for screening for an anti-neoplastic agent comprising the steps of (a) exposing cells to a chemical agent to be tested for antineoplastic activity, and (b) determining a change in expression of at least one gene of a signature gene set, or a sequence that is at least 95% identical thereto, wherein a change in expression is indicative of anti-neoplastic activity.
  • a change in expression is intended to mean a change include any activity of the gene, and may be an increase or decrease thereof.
  • such change in activity may be a change in expression or other activity of at least 1 such gene, such as 5 or 10, or more of the genes of a signature set, even as many as half of such genes or even of all of the genes of a particular gene set.
  • the gene expression to be measured is commonly assayed using RNA expression as an indicator.
  • RNA expression as an indicator.
  • gene expression either absolute or relative, such as where the expression of several different genes are being quantitatively evaluated and compared, for example, where chemical agents modulate the expression of more than one gene, such as a set of 3, 4, 5, or more genes, is determined by the relative expression of the RNAs encoded by such genes.
  • RNA may be isolated from samples in a variety of ways, including lysis and denaturation with a phenolic solution containing a chaotropic agent (e.g., triazol) followed by isopropanol precipitation, ethanol wash, and resuspension in aqueous solution; or lysis and denaturation followed by isolation on solid support, such as a Qiagen resin and reconstitution in aqueous solution; or lysis and denaturation in non-phenolic, aqueous solutions followed by enzymatic conversion of RNA to DNA template copies.
  • a chaotropic agent e.g., triazol
  • steady state RNA expression levels for the genes, and sets of genes, disclosed herein will have been obtained. It is the steady state level of such expression that is affected by potential anti-neoplastic agents as determined herein. Such steady state levels of expression are easily determined by any methods that are sensitive, specific and accurate.
  • Such methods include, but are in no way limited to, real time quantitative polymerase chain reaction (PCR), for example, using a Perkin-Elmer 7700 sequence detection system with gene specific primer probe combinations as designed using any of several commercially available software packages, such as Primer Express software.
  • PCR polymerase chain reaction
  • solid support based hybridization array technology using appropriate internal controls for quantitation, including filter, bead, or microchip based arrays, solid support based hybridization arrays using, for example, chemiluminescent, fluorescent, or electrochemical reaction based detection systems.
  • a set of genes useful in evaluating, or screening, or otherwise assaying, one or more chemical agents for anti-neoplastic activity in the assays disclosed herein will have already been shown to have differences in the ratios of steady state RNA levels in cancer cells , or tissues, relative to normal, or non-tumorous cells or tissues, or will have exhibited differences in the expression ratios in tumor samples compared to normal samples between genes in a given subset of the set of genes disclosed herein, or will have gene expression that has increased from undetectable levels to detectable levels, or vice versa, as the case may be, especially where sensitive detection methods are employed, or conversely will have decreased from detectable levels to undetectable levels with such procedures, especially sensitive procedures.
  • genes, and gene sequences, useful in practicing the methods of the present invention are genes that are found to be selectively expressed in, or not expressed in, cancer cells as compared to non-cancer cells, or in which expression is down-regulated or up-regulated, as the case may be, in cancerous cells as compared to non-cancerous cells.
  • these may include genes, or sets of genes, expressed in cancer cells but absent from, or inactive in, non-cancerous cells, or may include genes, or sets of genes, expressed in non-cancerous cells, but not expressed in cancer cells.
  • the genes useful in practicing the present invention may be more expressed, or less expressed, in a cancerous cell relative to a non- cancerous cell.
  • Such genes are generally those comprising the sequences of SEQ ID NO: 1 - 8447.
  • the present invention further relates to a process for determining the cancerous status of a test cell, comprising determining expression in said test cell of at least one gene that includes one of the nucleotide sequences selected from the sequences of SEQ ID NO: 1 - 8447, or a nucleotide sequence that is at least 95% identical thereto, and then comparing said expression to expression of said at least one gene in at least one cell known to be non-cancerous whereby a difference in said expression indicates that said cell is cancerous.
  • the present invention is directed to a process for determining the cancerous status of a cell to be tested, comprising determining the presence in said cell of at least one gene that includes one of the nucleotide sequences selected from the sequences of SEQ ID NO: 1 - 8447, including sequences having substantial identity homologous to said sequences, or characteristic fragments thereof, or the complements of any of the foregoing and then comparing the pattern of said gene presence and/or absence with that found for a cell known, or believed, to be non-cancerous, or normal, at least with respect to its genetic complement.
  • genes that include at least one of the sequences of SEQ ID NO: 1 - 8447 up regulation of expression in cancer cells (as compared to non-cancer cells, which may lack said genes, or said gene expression, altogether) is indicative of a cancerous, or potentially cancerous, condition.
  • the present invention relates to embodiments wherein the genetic pattern is the modulation of expression of more than one gene, preferably 3, 4, or 5 genes, and even includes patterns where there is a modulation of expression of as many as 10, or more, genes.
  • a genetic pattern is the modulation of expression of 5 genes in a cancerous cell as compared to a non-cancerous cell from the same tissue type, such as a cancerous colon cell or other cancerous tissue cell, such as any of the organs or tissues described herein as related to specifically recited SEQ ID NOs.
  • a non-cancerous cell of the same tissue or organ such a pattern indicates a likelihood that such genes (i.e., the modulation of expression of those 5 genes) is an indicator of cancerous status and thereby provides a means of diagnosing a cancerous, or potentially cancerous, status.
  • colon especially colon adenocarcinoma
  • SEQ ID NO: 334-522 would represent a signature set or signature gene set for colon. The same is true for each of the organs and tissues listed below with their respective signature sets or signature gene sets.
  • SEQ ID NO: 1068-2459 for breast, wherein SEQ ID NO: 1068-1255 represent genes expressed in infiltrating ductal carcinoma of the breast that are not expressed at detectable levels in normal breast, wherein SEQ ID NO: 1256-1459 represent genes expressed in breast carcinoma that are not expressed at detectable levels in normal breast, wherein SEQ ID NO: 1459-1664 represent genes expressed in infiltrating lobular carcinoma of the breast that are not expressed at detectable levels in normal breast, wherein SEQ ID NO: 1665-2067 represent genes expressed in normal breast that are absent or not expressed in infiltrating ductal carcinoma of the breast, and wherein SEQ ID NO: 2068-2459 represent genes expressed in normal breast cells but absent or not expressed in infiltrating lobular carcinoma of the breast that are not expressed at detectable levels in normal breast.
  • SEQ ID NO: 2460-2773 represent genes or gene sequences expressed in stomach cancer that are not expressed at detectable levels in normal stomach cells, and wherein SEQ ID NO: 2774-3027 represent genes or gene sequences expressed in normal stomach cells cancer that are not expressed at detectable levels in stomach cancer cells.
  • SEQ ID NO: 3028-5303 for lung, wherein SEQ ID NO: 3028-3119 represent genes or gene sequences expressed in lung adenocarcinoma that are not expressed at appreciable levels in normal lung cells, wherein SEQ ID NO: 3120-3322 represent genes or gene sequences expressed in normal lung cells that are not expressed at appreciable levels in lung adenocarcinoma, wherein SEQ ID NO: 3323-3570 represent genes or gene sequences expressed in non-cancerous lung tissue that are not expressed at appreciable levels in malignant lung samples, wherein SEQ ID NO: 3571-3777 represent genes or gene sequences expressed in malignant lung samples that are not expressed at appreciable levels in non-malignant lung cells, wherein SEQ ID NO: 3778-3836 represent genes or gene sequences expressed in both normal and malignant lung adenocarcinoma but are up-regulated by at least about 2 fold in lung adenocarcinoma, wherein SEQ ID NO: 3837-3980 represent genes or gene sequences
  • SEQ ID NO: 5304-5886 for thyroid, wherein SEQ ID NO: 5304-5408 represent genes or gene sequences expressed in thyroid papillary carcinoma that are not found in normal thyroid tissue, wherein SEQ ID NO: 5409-5602 represent genes or gene sequences expressed in normal thyroid cells that are not expressed in thyroid papillary carcinoma and wherein SEQ ID NO: 5603-5886 represent genes or gene sequences expressed at a level at least about a 5 fold higher level in thyroid papillary carcinoma relative to normal thyroid cells.
  • SEQ ID NO: 5887-6147 for esophagus, wherein SEQ ID NO: 5887-6015 represent genes or gene sequences expressed in esophagus adenocarcinoma but not in normal esophagus from the same patients and wherein SEQ ID NO: 6016-6147 represent genes or gene sequences expressed in normal esophagus but not in esophagus adenocarcinoma samples from the same patients.
  • SEQ ID NO: 6148-6472 for ovary, wherein SEQ ID NO: 6148-6371 represent genes or gene sequences expressed only in malignant ovarian carcinomas, wherein SEQ ID NO: 6372-6424 represent genes or gene sequences expressed only in normal ovarian tissues and wherein SEQ ID NO: 6425-6472 represent genes or gene sequences expressed only in metastatic ovarian cancer.
  • SEQ ID NO: 6473-7473 for kidney This further includes SEQ ID NO: 6473-7473 for kidney, wherein SEQ ID NO: 6473-7473 for kidney, wherein SEQ ID NO: 6473-7473 for kidney, wherein SEQ ID NO: 6473-7473 for kidney, wherein SEQ ID NO: 6473-7473 for kidney, wherein SEQ ID NO: 6473-7473 for kidney, wherein SEQ ID NO: 6473-7473 for kidney, wherein SEQ ID NO: 6473-7473 for kidney, wherein SEQ ID NO: 6473-7473 for kidney, wherein SEQ ID NO: 6473-7473 for kidney, wherein SEQ ID NO: 6473-7473 for kidney, wherein SEQ ID NO: 6473-7473 for kidney, wherein SEQ ID NO: 6473-7473 for kidney, wherein SEQ ID NO: 6473-7473 for kidney, wherein SEQ ID NO: 6473-7473 for kidney, wherein SEQ ID NO: 6473-7473 for kidney,
  • ID NO:6473-6615 represent genes or gene sequences expressed in normal kidney but not in clear cell carcinoma of the kidney
  • SEQ ID NO: 6616-6685 represent genes or gene sequences expressed in clear cell carcinoma cells but not in normal kidney cells
  • SEQ ID NO: 6686- 6973 represent genes or gene sequences expressed in normal kidney cells but not in renal cell carcinoma of the kidney
  • SEQ ID NO: 6974-7156 represent genes or gene sequences expressed in renal cell carcinoma but not in normal kidney
  • SEQ ID NO: 7157-7229 represent genes or gene sequences expressed in normal kidney but not in Wilm's tumor cells
  • SEQ ID NO: 7230-7473 represent genes or gene sequences expressed in Wilm's tumor but not in normal kidney cells.
  • SEQ ID NO: 7474-8131 for prostate, wherein SEQ ID NO: 7475-7833 represent genes or gene sequences expressed in prostate adenocarcinoma but not appreciably expressed in normal prostate cells, wherein SEQ ID NO: 7834-8071 represent genes or gene sequences expressed in normal prostate cells but not expressed at appreciable levels in prostate adenocarcinoma and wherein SEQ ID NO: 8072-8131 represent genes or gene sequences for ribosomal proteins that are highly expressed in prostate adenocarcinoma but are not expressed at appreciable levels in normal prostate cells.
  • SEQ ID NO: 8132-8447 for pancreas, wherein SEQ ID NO: 8132-8358 represent genes or gene sequences expressed in normal pancreas but not in pancreas adenocarcinoma and wherein SEQ ID NO: 8359-8447 represent genes or gene sequences expressed in pancreas adenocarcinoma but not in normal pancreas.
  • the gene patterns indicative of a cancerous state need not be characteristic of every cell found to be cancerous.
  • the methods disclosed herein are useful for detecting the presence of a cancerous condition within a tissue where less than all cells exhibit the complete pattern.
  • a set of selected genes comprising sequences homologous under stringent conditions, or at least 90%, preferably 95%, identical to at least one of the sequences of SEQ ID NO: 1 - 8447, and wherein the signature set is comprised of genes expressed and/or up-regulated in cancer cells relative to normal cells, as disclosed above for the signature gene sets used for practicing the invention, may be found, using appropriate probes, either DNA or RNA, to be present in as little as 60% of cells derived from a sample of tumorous, or malignant, tissue while being absent from as much as 60% of cells derived from corresponding non-cancerous, or otherwise normal, tissue (and thus being present in as much as 40% of such normal tissue cells).
  • such gene pattern is found to be present in at least 70% of cells drawn from a cancerous tissue and absent from at least 70% of a corresponding normal, non-cancerous, tissue sample. In an especially preferred embodiment, such gene pattern is found to be present in at least 80% of cells drawn from a cancerous tissue and absent from at least 80% of a corresponding normal, non-cancerous, tissue sample. In a most preferred embodiment, such gene pattern is found to be present in at least 90% of cells drawn from a cancerous tissue and absent from at least 90% of a corresponding normal, non-cancerous, tissue sample. In an additional embodiment, such gene pattern is found to be present in at least 100% of cells drawn from a cancerous tissue and absent from at least 100% of a corresponding normal, non-cancerous, tissue sample, although the latter embodiment may represent a rare occurrence.
  • the presence or absence of expression of one or more selected gene sequences may be indicative of a cancerous status for a given ceil, the mere presence or absence of such a gene pattern may not alone be sufficient to achieve a malignant condition and thus the level of expression of such gene pattern may also be a significant factor in determining the attainment of a cancerous state.
  • a pattern of genes may be present in both cancerous and non-cancerous cells, the level of expression, and determined by any of the methods disclosed herein, all of which are well known in the art, may differ between the cancerous versus the non-cancerous cells.
  • it becomes essential to also determine the level of expression of one or more of said genes as a separate means of diagnosing the presence of a cancerous status for a given cell, groups of cells, or tissues, either in culture or in situ.
  • a determination of an anticancer agent using the signature gene sets for the various organs and tissues described above is based on patterns of modulation of such genes so that increase or decrease in expression of a gene due to the presence of such a potential agent may or may not be meaningful.
  • the more genes in a gene set that are affected by said agent the more likely said agent is an effective therapeutic agent.
  • agents may have different abilities to affect the genes of a signature gene set.
  • a potential therapeutic agent say, agent A
  • agent B causes a gene or group of genes of a characteristic or signature gene set, or even all of the genes of said gene set, to exhibit decreased expression, such as where a lower amount of mRNA is expressed from said gene(s), or less protein is produced from said mRNA
  • a second potential agent say, agent B
  • agent B while modulating the activity of the same or related genes causes said expression to be reduced to half, such as where only half as much mRNA is transcribed or only half as much protein is translated from said mRNA as for agent A
  • agent B is considered to have twice as much therapeutic potential as agent A.
  • Such modulation or change of activity as determined using the assays disclosed herein may include either an increase or a decrease in activity of said genes or gene sequences.
  • an agent that down-regulates said gene or genes, or gene sequences, or prevents their expression entirely is considered a potential antitumor agent within the present disclosure.
  • an agent causes expression of a gene or genes, or gene sequences, expressed in normal cells but not in cancer cells, or where said agent up-regulates a gene or genes, or gene sequences, that are expressed in normal cells but not in cancer cells, or are up-regulated in normal cells but not in cancer cells, of the same organ or tissue type, said agent is considered to be a potential antitumor agent within the present disclosure.
  • the present invention also relates to a method for producing a product comprising identifying an agent according to one of the disclosed processes for identifying such an agent wherein said product is the data collected with respect to said agent as a result of said identification process and wherein said data is sufficient to convey the chemical character and/or structure and/or properties of said agent.
  • the present invention further relates to a process for determining the cancerous status of a cell to be tested, comprising determining the level of expression in said cell of at least one gene that includes one of the nucleotide sequences selected from the sequences of SEQ ID NO: 1 - 8447, including sequences substantially identical to said sequences, or characteristic fragments thereof, or the complements of any of the foregoing and then comparing said expression to that of a cell known to be non-cancerous whereby the difference in said expression indicates that said cell to be tested is cancerous.
  • said expression is determined for more than one of said genes, such as 2, 3, 4, 5, or more such genes, considered as a set, and even as many as a set of 10 such genes.
  • a set of genes, for example, 5 such genes may be found to be expressed at certain levels in cancer cells but are found to be expressed at lower levels (or not expressed at all) in non-cancerous, or normal, cells.
  • a set of, for example, 5 such genes may be found to be expressed in normal (i.e., non- cancerous) cells but expressed at lower levels (or not expressed at all) in cancer cells.
  • genes expressed in cancer cells but expressed at lower levels (or not at all) in non-cancer are selected from those that include one of the sequences, or fragments of sequences, including complementary sequences, selected from SEQ ID NO: 1 - 8447.
  • the processes of the present invention include embodiments wherein said expression is the expression of more than one said gene, possibly at least three said genes, preferably at least 5 said genes, or even as many as 10 or more said genes.
  • the process of the invention relates to situations wherein expression of said genes is higher in said cells to be tested than in said non-cancerous cells, or wherein expression of said genes is lower in said cells to be tested than in said non-cancerous cells.
  • the cancerous, or non-cancerous, status of a cell, or tissue sample may be readily ascertained.
  • colon or other cancers can be readily detected using the methods of the present invention.
  • nucleotide sequence disclosed with respect to a specific sequence ID number is only a portion of the nucleotide sequence that encodes expression of the gene.
  • expression of the gene may be determined by use of a nucleotide probe that hybridizes to messenger RNA (mRNA) transcribed from a portion of the gene other than the specific nucleotide sequence disclosed with reference to a sequence ID number as recited herein.
  • mRNA messenger RNA
  • the present invention further relates to a process for determining a cancer initiating, facilitating or suppressing gene comprising the steps of contacting a cell with a cancer modulating agent and determining a change in expression of a gene selected from the group consisting of the gene sequences of SEQ ID NO: 1 - 8447 and thereby identifying said gene as being a cancer initiating or facilitating gene.
  • genes within the signature gene sets disclosed herein as SEQ ID NO: 1 - 8447 are found to play a direct role in the initiation or progression of cancer or even other diseases and disease processes. Because changes in expression of these genes (either up-regulation or down- regulation) are linked to the disease state (i.e. cancer), the change in expression may contribute to the initiation or progression of the disease. For example, if a gene that is up-regulated is an oncogene, or if a gene that is down-regulated is a tumor suppressors, such a gene provides for a means of screening for small molecule therapeutics beyond screens based upon expression output alone.
  • genes that display up-regulation in cancer and whose elevated expression contributes to initiation or progression of disease represent targets in screens for small molecules that inhibit or block their function. Examples include, but are not be limited to, kinase inhibition, cellular proliferation, substrate analogs that block the active site of protein targets, etc. Similarly, genes that display down-regulation in cancer and whose absence results in initiation or progression of disease are valuable therapeutics for gene therapy.
  • genes there are a variety of different contexts in which genes have been evaluated as being involved in the cancerous process.
  • some genes may be oncogenes and encode proteins that are directly involved in the cancerous process and thereby promote the occurrence of cancer in an animal.
  • other genes may serve to suppress the cancerous state in a given cell or cell type and thereby work against a cancerous condition forming in an animal.
  • Other genes may simply be involved either directly or indirectly in the cancerous process or condition and may serve in an ancillary capacity with respect to the cancerous state. All such types of genes are deemed with those to be determined in accordance with the invention as disclosed herein.
  • the gene determined by said process of the invention may be an oncogene, or the gene determined by said process may be a cancer facilitating gene, the latter including a gene that directly or indirectly affects the cancerous process, either in the promotion of a cancerous condition or in facilitating the progress of cancerous growth or otherwise modulating the growth of cancer cells, either in vivo or ex vivo.
  • the gene determined by said process may be a cancer suppressor gene, which gene works either directly or indirectly to suppress the initiation or progress of a cancerous condition.
  • Such genes may work indirectly where their expression alters the activity of some other gene or gene expression product that is itself directly involved in initiating or facilitating the progress of a cancerous condition.
  • a gene that encodes a polypeptide, either wild or mutant in type, which polypeptide acts to suppress of tumor suppressor gene, or its expression product will thereby act indirectly to promote tumor growth.
  • the process of the present invention includes cancer modulating agents that are themselves either polypeptides, or small chemical entities, that affect the cancerous process, including initiation, suppression or facilitation of tumor growth, either in vivo or ex vivo.
  • Said cancer modulating agent may have the effect of increasing gene expression or said cancer modulating agent may have the effect of decreasing gene expression as such terms have been described herein.
  • the present invention also relates to a process for treating cancer comprising contacting a cancerous cell with an agent having activity against an expression product encoded by a gene sequence selected from the group consisting of SEQ ID NO: 1 - 8447.
  • genes within these signature gene sets represent individual targets for therapeutic intervention, based at least in part on their pattern(s) of expression.
  • genes within the signature gene sets that encode cell surface molecules and are up-regulated in cancer as compared to normal cells.
  • the proteins encoded by such genes due to their elevated expression in cancer cells, represent highly useful therapeutic targets for "targeted therapies" utilizing such affinity structures as, for example, antibodies coupled to some cytotoxic agent.
  • an antibody or equivalent molecule that can specifically recognize the cell surface molecule (which could include an artificial peptide, a surrogate ligand, and the like) that is coupled to some agent that can induce cell death or a block in cell cycling offers therapeutic promise against these proteins.
  • cell surface molecule which could include an artificial peptide, a surrogate ligand, and the like
  • agent that can induce cell death or a block in cell cycling offers therapeutic promise against these proteins.
  • suicide "bullets” against intracellular proteins include the use of so-called suicide "bullets" against intracellular proteins
  • the process of the present invention includes embodiments of the above-recited process wherein said cancer cell is contacted in vivo as well as ex vivo, preferably wherein said agent comprises a portion, or is part of an overall molecular structure, having affinity for said expression product.
  • said portion having affinity for said expression product is an antibody, especially where said expression product is a polypeptide or oligopeptide or comprises an oligopeptide portion, or comprises a polypeptide.
  • Such an agent can therefore be a single molecular structure, comprising both affinity portion and anti-cancer activity portions, wherein said portions are derived from separate molecules, or molecular structures, possessing such activity when separated and wherein such agent has been formed by combining said portions into one larger molecular structure, such as where said portions are combined into the form of an adduct.
  • Said anti- cancer and affinity portions may be joined covalently, such as in the form of a single polypeptide, or polypeptide-like, structure or may be joined non- covalently, such as by hydrophobic or electrostatic interactions, such structures having been formed by means well known in the chemical arts.
  • the anti-cancer and affinity portions may be formed from separate domains of a single molecule that exhibits, as part of the same chemical structure, more than one activity wherein one of the activities is against cancer cells, or tumor formation or growth, and the other activity is affinity for an expression product produced by expression of genes related to the cancerous process or condition.
  • a chemical agent such as a protein or other polypeptide
  • an agent such as an antibody
  • an agent having affinity for an expression product of a cancerous cell, such as a polypeptide or protein encoded by a gene related to the cancerous process, especially a gene sequence selected from the group consisting of the sequences of SEQ ID NO: 1 - 8447.
  • said expression product is a cell surface receptor, such as a protein or glycoprotein or lipoprotein, present on the surface of a cancer cell, such as where it is part of the plasma membrane of said cancer cell, and acts as a therapeutic target for the affinity portion of said anticancer agent and where, after binding of the affinity portion of such agent to the expression product, the anti-cancer portion of said agent acts against said expression product so as to neutralize its effects in initiating, facilitating or promoting tumor formation and/or growth.
  • a cell surface receptor such as a protein or glycoprotein or lipoprotein
  • binding of the agent to said expression product may, without more, have the effect of deterring cancer promotion, facilitation or growth, especially where the presence of said expression product is related, either intimately or only in an ancillary manner, to the development and growth of a tumor.
  • binding of said agent to said expression product will have the effect of negating said tumor promoting activity.
  • said agent is an apoptosis- inducing agent that induces cell suicide, thereby killing the cancer cell and halting tumor growth.
  • the present invention further relates to a process for determining a cancer initiating, facilitating or suppressing gene in a cancer cell comprising determining a change in expression of a gene sequence, especially where said sequence is one selected from the group consisting of the sequences of SEQ ID NO: 1 - 8447.
  • the processes of the present invention take advantage of the correlation of changes in mRNA expression profiles of these signature gene sets with potential (depending on the form of cancer) changes in DNA copy number of the chromosomal regions wherein these genes are located.
  • the precise nature of the change in mRNA expression e.g. a signature set of genes that are up-regulated at the transcriptional level
  • All cancers contain chromosomal rearrangements, which typically represent translocations, amplifications, or deletions of specific regions of genomic DNA.
  • a recurrent chromosomal rearrangement that is associated with a specific stage and type of cancer always affects a gene (or possibly genes) that play a direct and critical role in the initiation or progression of the disease.
  • Many of the known oncogenes or tumor suppressor genes that play direct roles in cancer have either been initially identified based upon their positional cloning from a recurrent chromosomal rearrangement or have been demonstrated to fall within a rearrangement subsequent to their cloning by other methods. In all cases, such genes display amplification at both the level of DNA copy number and at the level of transcriptional expression at the mRNA level.
  • At least some of the genes that are contained within signature gene sets disclosed herein display changes in their mRNA expression profiles (depending on the precise reading frame involved) within cancer samples due, in part, to changes in their DNA copy number as a result of specific chromosomal rearrangements in those cancer cells.
  • the utilities that follow from this are (i) that the genes contained within these signature gene sets offer a time saving shortcut to the identification of novel chromosomal rearrangements, amplifications, or deletions that are associated with cancer, and/or (ii) represent key genes affected by such chromosomal rearrangements, amplifications, or deletions and, therefore, play a key role in the initiation or progression of the disease.
  • Genes within the signature sets that identify changes in the DNA copy number thus afford an entry point into other forms of diagnostic assay for the initiation, staging, or progression of cancer to be conducted in tissue samples at the DNA level (e.g. if gene X identifies a novel chromosomal amplification associated with ⁇ cancer, then that specific chromosomal region defined by gene X would serve as the basis for a diagnostic assay for cancer, where genomic DNA is extracted from tissue samples and evaluated for the presence of the specific amplification), and also the rapid positional cloning of genes that play vital and direct roles in the initiation or progression of cancer.
  • said change in expression may be determined by determining a change in gene copy number, wherein said change in copy number is an increase in copy number or wherein said change in copy number is a decrease in copy number.
  • Such change in gene copy number may be determined by determining a change in expression of messenger RNA encoded by a particular gene sequence, especially where said sequence is one selected from the group consisting of the sequences of SEQ ID NO: 1 - 8447.
  • said gene may be a cancer initiating gene, a cancer facilitating gene, or a cancer suppressing gene.
  • a cancer facilitating gene is a gene that, while not directly initiating or suppressing tumor formation or growth, said gene acts, such as through the actions of its expression product, to direct, enhance, or otherwise facilitate the progress of the cancerous condition, including where such gene acts against genes, or gene expression products, that would otherwise have the effect of decreasing tumor formation and/or growth.
  • the present invention also provides a process for diagnosing a cancerous cell comprising determining a cancer initiating, facilitating or suppressing gene according to the above-described methods.
  • the present invention also relates to a process for treating cancer comprising inserting into a cancerous cell a gene construct comprising an anti-cancer gene operably linked to a promoter or enhancer element such that expression of said anti-cancer gene causes suppression of said cancer and wherein said promoter or enhancer element is a promoter or enhancer element modulating a gene sequence selected from the group consisting of the sequences of SEQ ID NO: 1 - 8447.
  • each signature set is a collection of genes that share a gross common pattern of transcriptional regulation in cancer vs. normal (e.g. a signature set of genes that are transcriptionally up-regulated in cancer).
  • analyzing and comparing the DNA sequences of the promoter regions of all the genes contained within the signature set serves to identify conserved stretches or motifs of sequences within subsets of genes that represent cis-acting elements that specifically drive a form of gene expression (e.g. increased transcriptional expression in cancer).
  • the identification of such cis-acting regulatory elements is then available for use in driving the cancer-specific expression of suicide genes or toxins via genetic therapy using technology already well known in the art.
  • said anti-cancer gene is a cancer suppressor gene or encodes a polypeptide having anticancer activity, especially where said polypeptide has apoptotic activity.
  • the present invention such insertion of said gene construct into a cancerous cell is accomplished in vivo, for example using a viral or plasmid vector.
  • a viral or plasmid vector Such methods can also be applied to in vitro uses.
  • the methods of the present invention are readily applicable to different forms of gene therapy, either where cells are genetically modified ex vivo and then administered to a host or where the gene modification is conducted in vivo using any of a number of suitable methods involving vectors especially suitable to such therapies, such as the use of special viral vectors, including adeno-associated viruses and adenoviruses, as well as retroviruses and specially constructed plasmids to accomplish such therapies.
  • special viral vectors including adeno-associated viruses and adenoviruses, as well as retroviruses and specially constructed plasmids to accomplish such therapies.
  • retroviruses and specially constructed plasmids to accomplish such therapies.
  • the present method also relates to a process for determining functionally related genes comprising contacting one or more gene sequences selected from the group consisting of the sequences of SEQ ID NO: 1 - 8447 with an agent that modulates expression of more than one gene in such group and thereby determining a subset of genes of said group.
  • said functionally related genes are genes modulating the same metabolic pathway or said genes are genes encoding functionally related polypeptides.
  • said genes are genes whose expression is modulated by the same transcriptional activator or enhancer sequence, especially where said transcriptional activator or enhancer increases, or otherwise modulates, the activity of a gene sequence selected from the group consisting of SEQ ID NO: 1 - 8447.
  • the signature gene set disclosed herein also find use as the basis for small molecule assays for therapeutics based upon changes in expression profile.
  • small molecule screens serve to identify changes in expression of genes within a signature set and thereby provide a tool for the identification of specific functional pathways and a means of assigning defined functions to novel genes.
  • monitoring the transcriptional expression of the genes contained within the signature sets disclosed herein forms the basis of an assay for small molecule therapeutics.
  • such screens facilitate the identification of small molecules that down-regulate the expression of the genes of the signature set within cancer cells. While such therapeutics make a cancer cell "look" more normal, based upon the expression of the genes within the signature set, what actually happens when such screens are put into practice is that all genes within the signature sets do not respond identically to each small molecule within a chemical compound library.
  • an average signature set contains 200 different genes, for example, and the expression of all 200 genes is monitored in response to a library of some 50,000 chemical compounds, and subsets of genes within the signature set consistently change their patterns of expression in response to particular chemicals (e.g., 10 of the genes always change expression in a coordinated way, such as down-regulation of one gene within the group of 10) then it always causes the down-regulation of the other 9 specific genes as well.
  • Such subsets or subgroups of genes within each signature set that change their expression in a coordinated way in response to chemical compounds represent genes that are located within a common metabolic, signaling, physiological, or functional pathway so that by analyzing and identifying such subsets one can (a) assign known genes and novel genes to specific pathways and (b) identify specific functions and functional roles for novel genes that are grouped into pathways with genes for which their functions are already characterized or described. For example, one might identify a subgroup of 10 genes within a signature set (5 known genes & 5 novel genes) that change expression in a coordinated fashion and for which the 5 known genes are involved in apoptosis thereby implicating the other 5 novel genes as playing a role in apoptotic cellular processes.
  • the processes disclosed according to the present invention at once provide a novel means of assigning function to genes, i.e. a novel method of functional genomics, and a means for identifying chemical compounds that have potential therapeutic effects on specific cellular pathways.
  • Such chemical compounds may have therapeutic relevance to a variety of diseases outside of cancer as well, in cases where such diseases are known or are demonstrated to involve the specific cellular pathway that is affected.
  • any reference to particular buffers, media, reagents, cells, culture conditions and the like are not intended to be limiting, but are to be read so as to include all related materials that one of ordinary skill in the art would recognize as being of interest or value in the particular context in which that discussion is presented. For example, it is often possible to substitute one buffer system or culture medium for another and still achieve similar, if not identical, results. Those of skill in the art will have sufficient knowledge of such systems and methodologies so as to be able, without undue experimentation, to make substitutions that will optimally serve their purposes in using the methods and procedures disclosed herein.
  • SW480 cells are grown to a density of 10 5 cells/cm 2 in Leibovitz's L-15 medium supplemented with 2 mM L-glutamine (90%) and 10% fetal bovine serum.
  • the cells are collected after treatment with 0.25% trypsin, 0.02% EDTA at 37°C for 2 to 5 minutes.
  • the trypsinized cells are then diluted with 30 ml growth medium and plated at a density of 50,000 cells per well in a 96 well plate (200 ⁇ l/well). The following day, cells are treated with either compound buffer alone, or compound buffer containing a chemical agent to be tested, for 24 hours.
  • RNA is quantitated and 10 ng of sample in 1 ⁇ l are added to 24 ⁇ l of Taqman reaction mix containing 1X PCR buffer, RNAsin, reverse transcriptase, nucleoside triphosphates, amplitaq gold, tween 20, glycerol, bovine serum albumin (BSA) and specific PCR primers and probes for a reference gene (18S RNA) and a test gene (Gene X). Reverse transcription is then carried out at 48°C for 30 minutes.
  • the sample is then applied to a Perlin Elmer 7700 sequence detector and heat denatured for 10 minutes at 95°C.
  • Amplification is performed through 40 cycles using 15 seconds annealing at 60°C followed by a 60 second extension at 72°C and 30 second denaturation at 95°C.
  • Data files are then captured and the data analyzed with the appropriate baseline windows and thresholds.
  • the quantitative difference between the target and reference genes is then calculated and a relative expression value determined for all of the samples used. This procedure is then repeated for each of the target genes in a given signature, or characteristic, set and the relative expression ratios for each pair of genes is determined (i.e., a ratio of expression is determined for each target gene versus each of the other genes for which expression is measured, where each gene's absolute expression is determined relative to the reference gene for each compound, or chemical agent, to be screened).
  • the samples are then scored and ranked according to the degree of alteration of the expression profile in the treated samples relative to the control.
  • the overall expression of the set of genes relative to the controls, as modulated by one chemical agent relative to another, is also ascertained. Chemical agents having the most effect on a given gene, or set of genes, are considered the most anti-neoplastic.

Abstract

Processes for assaying potential antitumor agents based on their modulation of the expression of specified genes, or sets, of suspected cancer cell genes are disclosed, along with methods for diagnosing cancerous, or potentially cancerous, conditions as a result of the expression, or patterns of expression, of such genes, or sets of genes. Also disclosed are methods for determining functionally related genes, or gene sets, as well as methods for treating cancer based on targeting expression products of such genes, or gene sets, and determining genes involved in the cancerous process.

Description

CANCER GENE DETERMINATION AND THERAPEUTIC SCREENING USING SIGNATURE GENE SETS
This application claims priority of U.S. Provisional Applications 60/209,473, filed 5 June 2000; 60/209,531 , filed 5 June 2000; 60/233,133, filed 18 September 2000; 60/233,617, filed 18 September 2000; 60/234,009, filed 20 September 2000; 60/234,034, filed 20 September 2000; 60/234,052, filed 20 September 2000; 60/234,509, filed 22 September 2000; 60/234,567, filed 22 September 2000; 60/234,923, filed 25 September 2000; 60/234,924, filed 25 September 2000; 60/235,077, filed 25 September 2000; 60/235,082, filed 25 September 2000; 60/235,134, filed 25 September 2000; 60/235,280, filed 25 September 2000; 60/235,637, filed 26 September 2000; 60/235,638, filed 26 September 2000; 60/235,711 , filed 27 September 2000; 60/235,720, filed 27 September 2000; 60/235,840, filed 27 September 2000; 60/235,863, filed 27 September 2000; 60/236,028, filed 28 September 2000; 60/236,032, filed 28 September 2000; 60/236,033, filed 28 September 2000; 60/236,034, filed 28 September 2000; 60/236,109, filed 28 September 2000; 60/236,111 , filed 28 September 2000; 60/236,842, filed 29 September 2000; 60/236,891, filed 29 September 2000; 60/237,172, filed 2 October 2000; 60/237,173, filed 2 October 2000; 60/237,278, filed 2 October 2000; 60/237,294, filed 2 October 2000; 60/237,295, filed 2 October 2000; 60/237,316, filed 2 October 2000; 60/237,425, filed 3 October 2000; 60/237,598, filed 3 October 2000; 60/237,604, filed 3 October 2000; 60/237,606, filed 3 October 2000; 60/237,608, filed 3 October 2000; 60/244,867, filed 1 November 2000; and 60/245,084, filed 1 November 2000. FIELD OF THE INVENTION
The present invention relates to methods of assaying potential anti- tumor agents based on their modulation of the expression of specified sets of genes and methods for diagnosing cancerous, or potentially cancerous, conditions as a result of the patterns of expression of such gene sets.
BACKGROUND OF THE INVENTION
Screening assays for novel drugs are based on the response of model cell based systems in vitro to treatment with specific compounds. Various measures of cellular response have been utilized, including the release of cytokines, alterations in cell surface markers, activation of specific enzymes, as well as alterations in ion flux and/or pH. Some such screens rely on specific genes, such as oncogenes (or gene mutations).
BRIEF SUMMARY OF THE INVENTION
In accordance with the present invention, there is provided characteristic sets of gene sequences whose expression, or non-expression, or change in expression, either an increase or decrease thereof, are indicative of the cancerous or non-cancerous status of a given cell. More particularly, such genes whose expression is changed in cancerous, as compared to non- cancerous cells, from a specific tissue (in particular, any of those disclosed herein) are genes that include one of the nucleotide sequences of SEQ ID NO: 1 - 8447, or sequences that are substantially identical to said sequences. Such a change in expression may be an increase or a decrease in expression or activity of the gene or gene sequences disclosed herein. It is another object of the present invention to provide methods of using such characteristic, or signature, gene sets as a basis for assaying the potential ability of selected chemical agents to modulate upward or downward the expression of said characteristic, or signature, gene sets.
It is a further object of the present invention to provide methods of detecting the expression, or non-expression, or amount of expression, of said characteristic, or signature, gene sets, or portions thereof, as a means of determining the cancerous, or non-cancerous, status (or potential cancerous status) of selected cells as grown in culture or as maintained in situ.
It is a still further object of the present invention to provide methods for treating cancerous conditions utilizing selected chemical agents as determined from their ability to modulate (i.e., increase or decrease) the selected characteristic, or signature, gene sets as disclosed herein, where said genes include, or comprise, one of the sequences of SEQ ID NO: 1 - 8447, or sequences substantially identical to said sequences.
In another aspect, the present invention relates to a process for determining a cancer initiating, facilitating or suppressing gene comprising the steps of contacting a cancerous cell with a cancer modulating agent and determining a change in expression of a gene selected from the group consisting of the gene sequences of SEQ ID NO: 1 - 8447 and thereby identifying said gene as being a cancer initiating or facilitating gene. Said genes may, for example, be oncogenes, cancer facilitating or promoting genes, or cancer suppressor genes. Said agents may increase or decrease gene expression.
The present invention also relates to a process for treating cancer comprising contacting a cancerous cell with an agent having activity against an expression product encoded by a gene sequence selected from the group consisting of SEQ ID NO: 1 - 8447, which process may be conducted either ex vivo or in vivo. Such agents may comprise an antibody or other molecule or portion that is specific for said expression product.
In another aspect, the present invention further relates to process for determining a cancer initiating, facilitating or suppressing gene in a cancer cell comprising determining a change in expression of a gene sequence selected from the group consisting of the sequences of SEQ ID NO: 1 - 8447. Such change in expression is especially a change to a difference in copy number and said difference, either an increase or decrease thereof, and wherein said change is monitored or otherwise determined as a change in messenger RNA formation. Such change can be readily used to diagnose a cancerous condition, either in vivo or ex vivo.
The present invention still further relates to a process for treating cancer comprising inserting into a cancerous cell a gene construct comprising an anti-cancer gene operably linked to a promoter or enhancer element such that expression of said anti-cancer gene causes suppression of said cancer and wherein said promoter or enhancer element is a promoter or enhancer element modulating a gene sequence selected from the group consisting of the sequences of SEQ ID NO: 1 - 8447, wherein said gene may be a cancer suppressor gene, or where said gene encodes a polypeptide having anticancer activity, such as one with apoptotic activity.
In an additional aspect, the present invention relates to a process for determining functionally related genes comprising contacting one or more gene sequences selected from the group consisting of the sequences of SEQ ID NO: 1 - 8447 with an agent that modulates expression of more than one gene in such group and thereby determining a subset of genes of said group. Said functionally related genes include genes modulating the same metabolic pathway or encoding functionally related polypeptides or where said expression is modulated by the same transcription activator or enhancer sequence. The present invention also relates to a method for producing a product comprising identifying an agent according to the process of claim
1 wherein said product is the data collected with respect to said agent as a result of said process and wherein said data is sufficient to convey the chemical structure and/or properties of said agent.
DETAILED SUMMARY OF THE INVENTION
The present invention relates to methods of assaying potential antitumor agents based on their modulation of the expression of specified sets of genes and methods for diagnosing cancerous, or potentially cancerous, conditions as a result of the patterns of expression of such gene sets and for determining cancer-inducing or regulating genes, and gene sets, based on common expression or regulation of such genes, or gene sets.
In accordance with the present invention, model cellular systems using cell lines, primary cells, or tissue samples are maintained in growth medium and may be treated with compounds that may be at a single concentration or at a range of concentrations. At specific times after treatment, cellular RNAs are isolated from the treated cells, primary cells or tumors, which RNAs are indicative of expression of selected genes. The cellular RNA is then divided and subjected to analysis that detects the presence and/or quantity of specific RNA transcripts, which transcripts may then be amplified for detection purposes using standard methodologies, such as, for example, reverse transcriptase polymerase chain reaction (RT-PCR), etc. The presence or absence, or levels, of specific RNA transcripts are determined from these measurements and a metric derived for the type and degree of response of the sample to the treated compound compared to control samples. Also in accordance with the present invention, there are disclosed herein characteristic, or signature, sets of genes and gene sequences whose expression is, or can be, as a result of the methods of the present invention, linked to, or used to characterize, the cancerous, or non-cancerous, status of the cells, or tissues, to be tested. Thus, the methods of the present invention identify novel anti-neoplastic agents based on their alteration of expression of small sets of characteristic, or indicator, or signature genes in specific model systems. The methods of the invention may therefore be used with a variety of cell lines or with primary samples from tumors maintained in vitro under suitable culture conditions for varying periods of time, or in situ in suitable animal models.
More particularly, certain genes have been identified that are expressed at levels in cancer cells that are different than the expression levels in non-cancer cells. In one instance, the identified genes are expressed at higher levels in cancer cells than in normal cells. In another instance, the identified genes are expressed at lower levels in cancer cells as compared to normal cells.
In accordance with the foregoing, the present invention relates to process for screening for an anti-neoplastic agent comprising the steps of:
(a) exposing cells to a chemical agent to be tested for antineoplastic activity, and
(b) determining a change in expression of at least one gene that includes one of the sequences of SEQ ID NOS: 1 - 8447, or a sequence that is at least 95% identical thereto,
wherein a change in expression is indicative of anti-neoplastic activity.
In particular embodiments, such change in expression may be an increase or a decrease in expression or activity. More particularly, the present invention relates to a process for screening for an anti-neoplastic agent comprising the steps of:
(a) exposing a known cancerous cell to a chemical agent to be tested for antineoplastic activity; (b) allowing said chemical agent to modulate the activity of one or more genes present in said cell wherein said genes include or comprise one of the sequences selected from the group consisting of the sequences of SEQ ID NO: 1 - 8447, sequences substantially identical to said sequences, or the complements of any of the foregoing; (c) determining the expression of one or more genes of step (b);
(d) comparing the expression of said genes in the presence or absence of exposure to said chemical agent;
wherein a difference in expression is indicative of the ability of anti- neoplastic activity.
In specific embodiments of the present invention, said chemical agent to be tested modulates the expression of more than one said gene, especially where it modulates at least two said genes, more especially where at least 3, or at least 5 of said genes, or even 10 or more of said genes in said signature set, are modulated. In a preferred embodiment, all of said genes are modulated.
In one embodiment of the present invention, said gene modulation is downward modulation, so that, as a result of exposure to the chemical agent to be tested, one or more genes of the cancerous cell will be expressed at a lower level (or not expressed at all) when exposed to the agent as compared to the expression when not exposed to the agent.
In a preferred embodiment a selected set of said genes are expressed in the reference cell but not expressed in the cell to be tested as a result of the exposure of the cell to be tested to the chemical agent. Thus, where said chemical agent causes the gene, or genes, of the tested cell to be expressed at a lower level than the same genes of the reference, this is indicative of downward modulation and indicates that the chemical agent to be tested has anti-neoplastic activity. In a separate embodiment, exposure of said cells to be tested to the chemical agent, especially one suspected of having anti-neoplastic activity, may result in upward modulation of said genes of the cell to be tested. Such upward modulation is interpreted as meaning that said genes are expressed where previously not expressed, or else are expressed in greater quantities when exposed to the agent as compared to non-exposure to the agent. Such upward modulation may be taken as indicative of anti-neoplastic activity by the tested chemical agent(s) of the gene, or genes, so modulated results in lower neoplastic activity on the part of such cells, such as where increased expression of the gene, or genes, results in decreased growth and/or increased differentiation of said cells away from the cancerous state.
The genes useful in the assay processes include, respectively, as a part thereof at least one of the sequences selected from the group consisting of the sequences of SEQ ID NO: 1 - 8447, or sequences substantially identical thereto. Such sequences also include sequences complementary to any of the sequences disclosed herein.
Genes including sequences at least 90% identical to a sequence selected from SEQ ID NO: 1 - 8447, preferably at least about 95% identical to such a sequence, more preferably at least about 98% identical to such sequence and most preferably 100% identical to such a sequence are specifically contemplated by all of the processes of the present invention. In addition, sequences encoding the same proteins as any of these sequences, regardless of the percent identity of such sequences, are also specifically contemplated by any of the methods of the present invention that rely on any or all of said sequences, regardless of how they are otherwise described or limited. Thus, any such sequences are available for use in carrying out any of the methods disclosed according to the invention. Such sequences also include any open reading frames, as defined herein, present within any of the sequences of SEQ ID NO: 1 - 8447.
Further in accordance with the present invention, the term "percent identity" or "percent identical," when referring to a sequence, means that a sequence is compared to a claimed or described sequence after alignment of the sequence to be compared (the "Compared Sequence") with the described or claimed sequence (the "Reference Sequence"). The Percent Identity is then determined according to the following formula:
Percent Identity = 100 [1-(C/R)]
wherein C is the number of differences between the Reference Sequence and the Compared Sequence over the length of alignment between the Reference Sequence and the Compared Sequence wherein (i) each base or amino acid in the Reference Sequence that does not have a corresponding aligned base or amino acid in the Compared Sequence and (ii) each gap in the Reference Sequence and (iii) each aligned base or amino acid in the Reference Sequence that is different from an aligned base or amino acid in the Compared Sequence, constitutes a difference; and R is the number of bases or amino acids in the Reference Sequence over the length of the alignment with the Compared Sequence with any gap created in the Reference Sequence also being counted as a base or amino acid.
If an alignment exists between the Compared Sequence and the
Reference Sequence for which the percent identity as calculated above is about equal to or greater than a specified minimum Percent Identity then the Compared Sequence has the specified minimum percent identity to the
Reference Sequence even though alignments may exist in which the hereinabove calculated Percent Identity is less than the specified Percent Identity.
As used herein, the terms "portion," "segment," and "fragment," when used in relation to polypeptides, refer to a continuous sequence of residues, such as amino acid residues, which sequence forms a subset of a larger sequence. For example, if a polypeptide were subjected to treatment with any of the common endopeptidases, such as trypsin or chymotrypsin, the oligopeptides resulting from such treatment would represent portions, segments or fragments of the starting polypeptide. When used in relation to a polynucleotides, such terms refer to the products produced by treatment of said polynucleotides with any of the common endonucleases, or any stretch of polynucleotides that could be synthetically synthesized.
As used herein and except as noted otherwise, all terms are defined as given below.
In accordance with the present invention, the term "DNA segment" or "DNA sequence" refers to a DNA polymer, in the form of a separate fragment or as a component of a larger DNA construct, which has been derived from DNA isolated at least once in substantially pure form, i.e., free of contaminating endogenous materials and in a quantity or concentration enabling identification, manipulation, and recovery of the segment and its component nucleotide sequences by standard biochemical methods, for example, using a cloning vector. Such segments are provided in the form of an open reading frame uninterrupted by internal nontranslated sequences, or introns, which are typically present in eukaryotic genes. Sequences of non- translated DNA may be present downstream from the open reading frame, where the same do not interfere with manipulation or expression of the coding regions. The term "coding region" refers to that portion of a gene which either naturally or normally codes for the expression product of that gene in its natural genomic environment, i.e., the region coding in vivo for the native expression product of the gene. The coding region can be from a normal, mutated or altered gene, or can even be from a DNA sequence, or gene, wholly synthesized in the laboratory using methods well known to those of skill in the art of DNA synthesis.
In accordance with the present invention, the term "nucleotide sequence" refers to a heteropolymer of deoxyribonucleotides. Generally, DNA segments encoding the proteins provided by this invention are assembled from cDNA fragments and short oligonucleotide linkers, or from a series of oligonucleotides, to provide a synthetic gene which is capable of being expressed in a recombinant transcriptional unit comprising regulatory elements derived from a microbial or viral operon.
The term "expression product" means that polypeptide or protein that is the natural translation product of the gene and any nucleic acid sequence coding equivalents resulting from genetic code degeneracy and thus coding for the same amino acid(s).
The term "fragment," when referring to a coding sequence, means a portion of DNA comprising less than the complete coding region whose expression product retains essentially the same biological function or activity as the expression product of the complete coding region.
The term "primer" means a short nucleic acid sequence that is paired with one strand of DNA and provides a free 3'-OH end at which a DNA polymerase starts synthesis of a deoxyribonucleotide chain.
The term "promoter" means a region of DNA involved in binding of RNA polymerase to initiate transcription. The term "enhancer" refers to a region of DNA that, when present and active, has the effect of increasing expression of a different DNA sequence that is being expressed, thereby increasing the amount of expression product formed from said different DNA sequence.
The term "open reading frame (ORF)" means a series of triplets coding for amino acids without any termination codons and is a sequence (potentially) translatable into protein.
As used herein, reference to a DNA sequence includes both single stranded and double stranded DNA. Thus, the specific sequence, unless the context indicates otherwise, refers to the single strand DNA of such sequence, the duplex of such sequence with its complement (double stranded
DNA) and the complement of such sequence.
In carrying out the foregoing assays, relative antineoplastic activity may be ascertained by the extent to which a given chemical agent modulates the expression of genes present in a cancerous cell. Thus, a first chemical agent that modulates the expression of a gene associated with the cancerous state (i.e., a gene that includes one of the sequences disclosed herein and present in cancerous cells) to a larger degree than a second chemical agent tested by the assays of the invention is thereby deemed to have higher, or more desirable, or more advantageous, anti-neoplastic activity than said second chemical agent. Alternatively, where first and second chemical agents modulate expression of more than one of said genes, but where the second modulates expression of, for example, five said genes, whereas the first modulates expression of only three of said genes, especially where the three form a subset of the five, then the second chemical agent is deemed a more potent anti-neoplastic agent than the first. Such anti-neoplastic activity, as determined using the assays of the present invention, may necessarily include combinations of the foregoing possibilities, which are in no way to be considered limiting. In utilizing these gene sequences for the assays according to the invention, the genes whose activity is to be determined with and without the presence of the compound to be evaluated for antitumor activity may be any one, or several, or any combination of the gene sequences disclosed herein as SEQ ID NO: 1 - 8447. However, how the gene sequences are employed in such assays depends on the pattern of gene expression disclosed for the signature sets for the different organs and tissues. For example, a sequence that is expressed in cancerous cells but not in normal cells will identify a a potential anticancer agent by that agent's ability to decrease expression of the sequence, or sequences, in tumor cells. Conversely, a sequence, or sequences, expressed in normal but not tumor cells will identify a potential antitumor agent by its ability to increase expression in the tumor cells. The same relationship holds true where the sequences are expressed in both cancer and normal cells but are expressed at a higher level in one than in the other, and vice versa. Based on the expression patterns disclosed for the gene sequences and signature sets disclosed herein, it should be readily apparent to those skilled in the art how to conduct assays for potential antitumor agents using the signature gene sets. The same holds true where the sequences, or signature gene sets, are utilized to determine the cancerous state of a cell or use of an agent to treat a cancerous condition.
Thus, in one aspect, the present invention relates to a process for screening for an anti-neoplastic agent comprising the steps of (a) exposing cells to a chemical agent to be tested for antineoplastic activity, and (b) determining a change in expression of at least one gene of a signature gene set, or a sequence that is at least 95% identical thereto, wherein a change in expression is indicative of anti-neoplastic activity. Such change in expression is intended to mean a change include any activity of the gene, and may be an increase or decrease thereof. In addition, such change in activity may be a change in expression or other activity of at least 1 such gene, such as 5 or 10, or more of the genes of a signature set, even as many as half of such genes or even of all of the genes of a particular gene set. The gene expression to be measured is commonly assayed using RNA expression as an indicator. Thus, the greater the level of RNA (messenger RNA) detected the higher the level of expression of the corresponding gene. Thus, gene expression, either absolute or relative, such as where the expression of several different genes are being quantitatively evaluated and compared, for example, where chemical agents modulate the expression of more than one gene, such as a set of 3, 4, 5, or more genes, is determined by the relative expression of the RNAs encoded by such genes.
RNA may be isolated from samples in a variety of ways, including lysis and denaturation with a phenolic solution containing a chaotropic agent (e.g., triazol) followed by isopropanol precipitation, ethanol wash, and resuspension in aqueous solution; or lysis and denaturation followed by isolation on solid support, such as a Qiagen resin and reconstitution in aqueous solution; or lysis and denaturation in non-phenolic, aqueous solutions followed by enzymatic conversion of RNA to DNA template copies.
Normally, prior to applying the processes of the invention, steady state RNA expression levels for the genes, and sets of genes, disclosed herein will have been obtained. It is the steady state level of such expression that is affected by potential anti-neoplastic agents as determined herein. Such steady state levels of expression are easily determined by any methods that are sensitive, specific and accurate. Such methods include, but are in no way limited to, real time quantitative polymerase chain reaction (PCR), for example, using a Perkin-Elmer 7700 sequence detection system with gene specific primer probe combinations as designed using any of several commercially available software packages, such as Primer Express software., solid support based hybridization array technology using appropriate internal controls for quantitation, including filter, bead, or microchip based arrays, solid support based hybridization arrays using, for example, chemiluminescent, fluorescent, or electrochemical reaction based detection systems. In one embodiment of the present invention, a set of genes useful in evaluating, or screening, or otherwise assaying, one or more chemical agents for anti-neoplastic activity in the assays disclosed herein will have already been shown to have differences in the ratios of steady state RNA levels in cancer cells , or tissues, relative to normal, or non-tumorous cells or tissues, or will have exhibited differences in the expression ratios in tumor samples compared to normal samples between genes in a given subset of the set of genes disclosed herein, or will have gene expression that has increased from undetectable levels to detectable levels, or vice versa, as the case may be, especially where sensitive detection methods are employed, or conversely will have decreased from detectable levels to undetectable levels with such procedures, especially sensitive procedures.
The genes, and gene sequences, useful in practicing the methods of the present invention are genes that are found to be selectively expressed in, or not expressed in, cancer cells as compared to non-cancer cells, or in which expression is down-regulated or up-regulated, as the case may be, in cancerous cells as compared to non-cancerous cells. Thus, these may include genes, or sets of genes, expressed in cancer cells but absent from, or inactive in, non-cancerous cells, or may include genes, or sets of genes, expressed in non-cancerous cells, but not expressed in cancer cells. Alternatively, the genes useful in practicing the present invention may be more expressed, or less expressed, in a cancerous cell relative to a non- cancerous cell. Such genes are generally those comprising the sequences of SEQ ID NO: 1 - 8447.
All of these sequences are provided herewith on CD-ROM only.
In accordance with the foregoing, the present invention further relates to a process for determining the cancerous status of a test cell, comprising determining expression in said test cell of at least one gene that includes one of the nucleotide sequences selected from the sequences of SEQ ID NO: 1 - 8447, or a nucleotide sequence that is at least 95% identical thereto, and then comparing said expression to expression of said at least one gene in at least one cell known to be non-cancerous whereby a difference in said expression indicates that said cell is cancerous.
In a particular embodiment, the present invention is directed to a process for determining the cancerous status of a cell to be tested, comprising determining the presence in said cell of at least one gene that includes one of the nucleotide sequences selected from the sequences of SEQ ID NO: 1 - 8447, including sequences having substantial identity homologous to said sequences, or characteristic fragments thereof, or the complements of any of the foregoing and then comparing the pattern of said gene presence and/or absence with that found for a cell known, or believed, to be non-cancerous, or normal, at least with respect to its genetic complement.
With respect to genes that include at least one of the sequences of SEQ ID NO: 1 - 8447, up regulation of expression in cancer cells (as compared to non-cancer cells, which may lack said genes, or said gene expression, altogether) is indicative of a cancerous, or potentially cancerous, condition.
In specific embodiments, the present invention relates to embodiments wherein the genetic pattern is the modulation of expression of more than one gene, preferably 3, 4, or 5 genes, and even includes patterns where there is a modulation of expression of as many as 10, or more, genes. Thus, where a genetic pattern is the modulation of expression of 5 genes in a cancerous cell as compared to a non-cancerous cell from the same tissue type, such as a cancerous colon cell or other cancerous tissue cell, such as any of the organs or tissues described herein as related to specifically recited SEQ ID NOs., versus a non-cancerous cell of the same tissue or organ, such a pattern indicates a likelihood that such genes (i.e., the modulation of expression of those 5 genes) is an indicator of cancerous status and thereby provides a means of diagnosing a cancerous, or potentially cancerous, status. The absence of a specific set of genes from cancerous cells where said genes are present in otherwise normal cells, especially those of a similar type, is also indicative of a correlation with the cancerous state and thus can likewise be used as a means of diagnosing the cancerous state in other cells suspected of being cancerous.
For example, with respect to colon, especially colon adenocarcinoma, this would include SEQ ID NO: 1-333 (expressed in normal colon cells but not in colon cancer cells), SEQ ID NO: 334-522 (expressed at elevated levels in colon adenocarcinoma but not expressed in normal colon cells), SEQ ID NO: 523-837 (expressed at reduced levels, more than 2.09 fold, in colon adenocarcinoma but not in normal colon cells) and SEQ ID NO: 838-1067 (expressed at elevated (at least 2.1 fold) levels in colon adenocarcinoma but not elevated in normal colon cells). Thus, for colon the above groupings of sequences represent four signature gene sets for colon. For example, SEQ ID NO: 334-522 would represent a signature set or signature gene set for colon. The same is true for each of the organs and tissues listed below with their respective signature sets or signature gene sets.
In the same way as for colon, other gene sequences are indicative of the cancerous or normal state of other organs and tissues. Thus, as disclosed herein, these would include SEQ ID NO: 1068-2459 for breast, wherein SEQ ID NO: 1068-1255 represent genes expressed in infiltrating ductal carcinoma of the breast that are not expressed at detectable levels in normal breast, wherein SEQ ID NO: 1256-1459 represent genes expressed in breast carcinoma that are not expressed at detectable levels in normal breast, wherein SEQ ID NO: 1459-1664 represent genes expressed in infiltrating lobular carcinoma of the breast that are not expressed at detectable levels in normal breast, wherein SEQ ID NO: 1665-2067 represent genes expressed in normal breast that are absent or not expressed in infiltrating ductal carcinoma of the breast, and wherein SEQ ID NO: 2068-2459 represent genes expressed in normal breast cells but absent or not expressed in infiltrating lobular carcinoma of the breast that are not expressed at detectable levels in normal breast.
This further includes SEQ ID NO: 2460-3027 for stomach, wherein
SEQ ID NO: 2460-2773 represent genes or gene sequences expressed in stomach cancer that are not expressed at detectable levels in normal stomach cells, and wherein SEQ ID NO: 2774-3027 represent genes or gene sequences expressed in normal stomach cells cancer that are not expressed at detectable levels in stomach cancer cells.
This further includes SEQ ID NO:3028-5303 for lung, wherein SEQ ID NO: 3028-3119 represent genes or gene sequences expressed in lung adenocarcinoma that are not expressed at appreciable levels in normal lung cells, wherein SEQ ID NO: 3120-3322 represent genes or gene sequences expressed in normal lung cells that are not expressed at appreciable levels in lung adenocarcinoma, wherein SEQ ID NO: 3323-3570 represent genes or gene sequences expressed in non-cancerous lung tissue that are not expressed at appreciable levels in malignant lung samples, wherein SEQ ID NO: 3571-3777 represent genes or gene sequences expressed in malignant lung samples that are not expressed at appreciable levels in non-malignant lung cells, wherein SEQ ID NO: 3778-3836 represent genes or gene sequences expressed in both normal and malignant lung adenocarcinoma but are up-regulated by at least about 2 fold in lung adenocarcinoma, wherein SEQ ID NO: 3837-3980 represent genes or gene sequences expressed at appreciable levels in normal lung samples but are not typically expressed in lung squamous cell carcinoma, wherein SEQ ID NO: 3981-4215 represent genes or gene sequences expressed in normal lung tissue but not ordinarily expressed in neuroendocrine carcinoma of the lung, wherein SEQ ID NO: 4216-4634 represent genes or gene sequences expressed at appreciable levels in lung neuroendocrine carcinoma that are not expressed at detectable levels in normal lung, wherein SEQ ID NO: 4635-4877 represent genes or gene sequences expressed in lung squamous cell carcinoma that are not expressed at detectable levels in normal lung, and wherein SEQ ID NO: 4878- 5303 represent genes or gene sequences expressed in normal lung and lung adenocarcinoma but are down-regulated or under-expressed in lung adenocarcinoma relative to normal lung tissues.
This further includes SEQ ID NO: 5304-5886 for thyroid, wherein SEQ ID NO: 5304-5408 represent genes or gene sequences expressed in thyroid papillary carcinoma that are not found in normal thyroid tissue, wherein SEQ ID NO: 5409-5602 represent genes or gene sequences expressed in normal thyroid cells that are not expressed in thyroid papillary carcinoma and wherein SEQ ID NO: 5603-5886 represent genes or gene sequences expressed at a level at least about a 5 fold higher level in thyroid papillary carcinoma relative to normal thyroid cells.
This further includes SEQ ID NO: 5887-6147 for esophagus, wherein SEQ ID NO: 5887-6015 represent genes or gene sequences expressed in esophagus adenocarcinoma but not in normal esophagus from the same patients and wherein SEQ ID NO: 6016-6147 represent genes or gene sequences expressed in normal esophagus but not in esophagus adenocarcinoma samples from the same patients.
This further includes SEQ ID NO: 6148-6472 for ovary, wherein SEQ ID NO: 6148-6371 represent genes or gene sequences expressed only in malignant ovarian carcinomas, wherein SEQ ID NO: 6372-6424 represent genes or gene sequences expressed only in normal ovarian tissues and wherein SEQ ID NO: 6425-6472 represent genes or gene sequences expressed only in metastatic ovarian cancer.
This further includes SEQ ID NO: 6473-7473 for kidney, wherein SEQ
ID NO:6473-6615 represent genes or gene sequences expressed in normal kidney but not in clear cell carcinoma of the kidney, wherein SEQ ID NO: 6616-6685 represent genes or gene sequences expressed in clear cell carcinoma cells but not in normal kidney cells, wherein SEQ ID NO: 6686- 6973 represent genes or gene sequences expressed in normal kidney cells but not in renal cell carcinoma of the kidney, wherein SEQ ID NO: 6974-7156 represent genes or gene sequences expressed in renal cell carcinoma but not in normal kidney, wherein SEQ ID NO: 7157-7229 represent genes or gene sequences expressed in normal kidney but not in Wilm's tumor cells, and wherein SEQ ID NO: 7230-7473 represent genes or gene sequences expressed in Wilm's tumor but not in normal kidney cells.
This further includes SEQ ID NO: 7474-8131 for prostate, wherein SEQ ID NO: 7475-7833 represent genes or gene sequences expressed in prostate adenocarcinoma but not appreciably expressed in normal prostate cells, wherein SEQ ID NO: 7834-8071 represent genes or gene sequences expressed in normal prostate cells but not expressed at appreciable levels in prostate adenocarcinoma and wherein SEQ ID NO: 8072-8131 represent genes or gene sequences for ribosomal proteins that are highly expressed in prostate adenocarcinoma but are not expressed at appreciable levels in normal prostate cells.
This further includes SEQ ID NO: 8132-8447 for pancreas, wherein SEQ ID NO: 8132-8358 represent genes or gene sequences expressed in normal pancreas but not in pancreas adenocarcinoma and wherein SEQ ID NO: 8359-8447 represent genes or gene sequences expressed in pancreas adenocarcinoma but not in normal pancreas.
The gene patterns indicative of a cancerous state need not be characteristic of every cell found to be cancerous. Thus, the methods disclosed herein are useful for detecting the presence of a cancerous condition within a tissue where less than all cells exhibit the complete pattern. For example, a set of selected genes, comprising sequences homologous under stringent conditions, or at least 90%, preferably 95%, identical to at least one of the sequences of SEQ ID NO: 1 - 8447, and wherein the signature set is comprised of genes expressed and/or up-regulated in cancer cells relative to normal cells, as disclosed above for the signature gene sets used for practicing the invention, may be found, using appropriate probes, either DNA or RNA, to be present in as little as 60% of cells derived from a sample of tumorous, or malignant, tissue while being absent from as much as 60% of cells derived from corresponding non-cancerous, or otherwise normal, tissue (and thus being present in as much as 40% of such normal tissue cells). In a preferred embodiment, such gene pattern is found to be present in at least 70% of cells drawn from a cancerous tissue and absent from at least 70% of a corresponding normal, non-cancerous, tissue sample. In an especially preferred embodiment, such gene pattern is found to be present in at least 80% of cells drawn from a cancerous tissue and absent from at least 80% of a corresponding normal, non-cancerous, tissue sample. In a most preferred embodiment, such gene pattern is found to be present in at least 90% of cells drawn from a cancerous tissue and absent from at least 90% of a corresponding normal, non-cancerous, tissue sample. In an additional embodiment, such gene pattern is found to be present in at least 100% of cells drawn from a cancerous tissue and absent from at least 100% of a corresponding normal, non-cancerous, tissue sample, although the latter embodiment may represent a rare occurrence.
Conversely, where the signature set is expressed or up-regulated in normal cells versus cancerous cells, as disclosed herein, expression in the normal cells but not in suspected cancerous cells may confirm a cancerous state in the suspected cancerous sample. The same is true for assays disclosed herein for potential antitumor agents.
Although the presence or absence of expression of one or more selected gene sequences may be indicative of a cancerous status for a given ceil, the mere presence or absence of such a gene pattern may not alone be sufficient to achieve a malignant condition and thus the level of expression of such gene pattern may also be a significant factor in determining the attainment of a cancerous state. Thus, while a pattern of genes may be present in both cancerous and non-cancerous cells, the level of expression, and determined by any of the methods disclosed herein, all of which are well known in the art, may differ between the cancerous versus the non-cancerous cells. Thus, it becomes essential to also determine the level of expression of one or more of said genes as a separate means of diagnosing the presence of a cancerous status for a given cell, groups of cells, or tissues, either in culture or in situ.
In accordance with the invention disclosed herein, a determination of an anticancer agent using the signature gene sets for the various organs and tissues described above is based on patterns of modulation of such genes so that increase or decrease in expression of a gene due to the presence of such a potential agent may or may not be meaningful. Thus, the more genes in a gene set that are affected by said agent the more likely said agent is an effective therapeutic agent.
In addition, different agents may have different abilities to affect the genes of a signature gene set. For example, if a potential therapeutic agent, say, agent A, causes a gene or group of genes of a characteristic or signature gene set, or even all of the genes of said gene set, to exhibit decreased expression, such as where a lower amount of mRNA is expressed from said gene(s), or less protein is produced from said mRNA, but a second potential agent, say, agent B, while modulating the activity of the same or related genes causes said expression to be reduced to half, such as where only half as much mRNA is transcribed or only half as much protein is translated from said mRNA as for agent A, then agent B is considered to have twice as much therapeutic potential as agent A.
Such modulation or change of activity as determined using the assays disclosed herein may include either an increase or a decrease in activity of said genes or gene sequences. Thus, where a gene is expressed in cancer cells but not in normal cells, or is up-regulated in cancer cells relative to normal cells, of the same organ or tissue type, an agent that down-regulates said gene or genes, or gene sequences, or prevents their expression entirely, is considered a potential antitumor agent within the present disclosure. Conversely, where an agent causes expression of a gene or genes, or gene sequences, expressed in normal cells but not in cancer cells, or where said agent up-regulates a gene or genes, or gene sequences, that are expressed in normal cells but not in cancer cells, or are up-regulated in normal cells but not in cancer cells, of the same organ or tissue type, said agent is considered to be a potential antitumor agent within the present disclosure.
The present invention also relates to a method for producing a product comprising identifying an agent according to one of the disclosed processes for identifying such an agent wherein said product is the data collected with respect to said agent as a result of said identification process and wherein said data is sufficient to convey the chemical character and/or structure and/or properties of said agent.
In accordance with the foregoing, the present invention further relates to a process for determining the cancerous status of a cell to be tested, comprising determining the level of expression in said cell of at least one gene that includes one of the nucleotide sequences selected from the sequences of SEQ ID NO: 1 - 8447, including sequences substantially identical to said sequences, or characteristic fragments thereof, or the complements of any of the foregoing and then comparing said expression to that of a cell known to be non-cancerous whereby the difference in said expression indicates that said cell to be tested is cancerous.
In specific embodiments of the present invention, said expression is determined for more than one of said genes, such as 2, 3, 4, 5, or more such genes, considered as a set, and even as many as a set of 10 such genes. A set of genes, for example, 5 such genes, may be found to be expressed at certain levels in cancer cells but are found to be expressed at lower levels (or not expressed at all) in non-cancerous, or normal, cells. Conversely, a set of, for example, 5 such genes may be found to be expressed in normal (i.e., non- cancerous) cells but expressed at lower levels (or not expressed at all) in cancer cells. Thus, by determining the set or pattern of genes expressed in cancer cells but expressed at lower levels (or not at all) in non-cancer, or vice versa, a method is achieved for diagnosing cancerous conditions wherein said genes are selected from those that include one of the sequences, or fragments of sequences, including complementary sequences, selected from SEQ ID NO: 1 - 8447.
In specific embodiments, the processes of the present invention include embodiments wherein said expression is the expression of more than one said gene, possibly at least three said genes, preferably at least 5 said genes, or even as many as 10 or more said genes.
In other embodiments, the process of the invention relates to situations wherein expression of said genes is higher in said cells to be tested than in said non-cancerous cells, or wherein expression of said genes is lower in said cells to be tested than in said non-cancerous cells.
Using the methods disclosed herein, the cancerous, or non-cancerous, status of a cell, or tissue sample, may be readily ascertained. For example, colon or other cancers can be readily detected using the methods of the present invention.
In accordance with the invention, although gene expression for a gene that includes as a portion thereof one of the nucleotide sequences of SEQ ID
NO: 1 - 8447, is preferably determined by use of a probe that is a fragment of such nucleotide sequence, it is to be understood that the probe may be formed from a different portion of the gene. Thus, for each gene of the signature sets of the present invention, the nucleotide sequence disclosed with respect to a specific sequence ID number is only a portion of the nucleotide sequence that encodes expression of the gene. As a result, expression of the gene may be determined by use of a nucleotide probe that hybridizes to messenger RNA (mRNA) transcribed from a portion of the gene other than the specific nucleotide sequence disclosed with reference to a sequence ID number as recited herein.
The present invention further relates to a process for determining a cancer initiating, facilitating or suppressing gene comprising the steps of contacting a cell with a cancer modulating agent and determining a change in expression of a gene selected from the group consisting of the gene sequences of SEQ ID NO: 1 - 8447 and thereby identifying said gene as being a cancer initiating or facilitating gene.
Thus, some or all of the genes within the signature gene sets disclosed herein as SEQ ID NO: 1 - 8447 are found to play a direct role in the initiation or progression of cancer or even other diseases and disease processes. Because changes in expression of these genes (either up-regulation or down- regulation) are linked to the disease state (i.e. cancer), the change in expression may contribute to the initiation or progression of the disease. For example, if a gene that is up-regulated is an oncogene, or if a gene that is down-regulated is a tumor suppressors, such a gene provides for a means of screening for small molecule therapeutics beyond screens based upon expression output alone. For example, genes that display up-regulation in cancer and whose elevated expression contributes to initiation or progression of disease represent targets in screens for small molecules that inhibit or block their function. Examples include, but are not be limited to, kinase inhibition, cellular proliferation, substrate analogs that block the active site of protein targets, etc. Similarly, genes that display down-regulation in cancer and whose absence results in initiation or progression of disease are valuable therapeutics for gene therapy.
It should be noted that there are a variety of different contexts in which genes have been evaluated as being involved in the cancerous process. Thus, some genes may be oncogenes and encode proteins that are directly involved in the cancerous process and thereby promote the occurrence of cancer in an animal. In addition, other genes may serve to suppress the cancerous state in a given cell or cell type and thereby work against a cancerous condition forming in an animal. Other genes may simply be involved either directly or indirectly in the cancerous process or condition and may serve in an ancillary capacity with respect to the cancerous state. All such types of genes are deemed with those to be determined in accordance with the invention as disclosed herein. Thus, the gene determined by said process of the invention may be an oncogene, or the gene determined by said process may be a cancer facilitating gene, the latter including a gene that directly or indirectly affects the cancerous process, either in the promotion of a cancerous condition or in facilitating the progress of cancerous growth or otherwise modulating the growth of cancer cells, either in vivo or ex vivo. In addition, the gene determined by said process may be a cancer suppressor gene, which gene works either directly or indirectly to suppress the initiation or progress of a cancerous condition. Such genes may work indirectly where their expression alters the activity of some other gene or gene expression product that is itself directly involved in initiating or facilitating the progress of a cancerous condition. For example, a gene that encodes a polypeptide, either wild or mutant in type, which polypeptide acts to suppress of tumor suppressor gene, or its expression product, will thereby act indirectly to promote tumor growth.
In accordance with the foregoing, the process of the present invention includes cancer modulating agents that are themselves either polypeptides, or small chemical entities, that affect the cancerous process, including initiation, suppression or facilitation of tumor growth, either in vivo or ex vivo. Said cancer modulating agent may have the effect of increasing gene expression or said cancer modulating agent may have the effect of decreasing gene expression as such terms have been described herein.
In keeping with the disclosure herein, the present invention also relates to a process for treating cancer comprising contacting a cancerous cell with an agent having activity against an expression product encoded by a gene sequence selected from the group consisting of SEQ ID NO: 1 - 8447.
Thus, some or all of the genes within these signature gene sets represent individual targets for therapeutic intervention, based at least in part on their pattern(s) of expression. For example, genes within the signature gene sets that encode cell surface molecules and are up-regulated in cancer as compared to normal cells. The proteins encoded by such genes, due to their elevated expression in cancer cells, represent highly useful therapeutic targets for "targeted therapies" utilizing such affinity structures as, for example, antibodies coupled to some cytotoxic agent. In such methodology, it is advantageous that nothing need be known about the endogenous ligands or binding partners for such cell surface molecules. Rather, an antibody or equivalent molecule that can specifically recognize the cell surface molecule (which could include an artificial peptide, a surrogate ligand, and the like) that is coupled to some agent that can induce cell death or a block in cell cycling offers therapeutic promise against these proteins. Thus, such approaches include the use of so-called suicide "bullets" against intracellular proteins
The process of the present invention includes embodiments of the above-recited process wherein said cancer cell is contacted in vivo as well as ex vivo, preferably wherein said agent comprises a portion, or is part of an overall molecular structure, having affinity for said expression product. In one such embodiment, said portion having affinity for said expression product is an antibody, especially where said expression product is a polypeptide or oligopeptide or comprises an oligopeptide portion, or comprises a polypeptide.
Such an agent can therefore be a single molecular structure, comprising both affinity portion and anti-cancer activity portions, wherein said portions are derived from separate molecules, or molecular structures, possessing such activity when separated and wherein such agent has been formed by combining said portions into one larger molecular structure, such as where said portions are combined into the form of an adduct. Said anti- cancer and affinity portions may be joined covalently, such as in the form of a single polypeptide, or polypeptide-like, structure or may be joined non- covalently, such as by hydrophobic or electrostatic interactions, such structures having been formed by means well known in the chemical arts. Alternatively, the anti-cancer and affinity portions may be formed from separate domains of a single molecule that exhibits, as part of the same chemical structure, more than one activity wherein one of the activities is against cancer cells, or tumor formation or growth, and the other activity is affinity for an expression product produced by expression of genes related to the cancerous process or condition.
In one embodiment of the present invention, a chemical agent, such as a protein or other polypeptide, is joined to an agent, such as an antibody, having affinity for an expression product of a cancerous cell, such as a polypeptide or protein encoded by a gene related to the cancerous process, especially a gene sequence selected from the group consisting of the sequences of SEQ ID NO: 1 - 8447. In a specific embodiment, said expression product is a cell surface receptor, such as a protein or glycoprotein or lipoprotein, present on the surface of a cancer cell, such as where it is part of the plasma membrane of said cancer cell, and acts as a therapeutic target for the affinity portion of said anticancer agent and where, after binding of the affinity portion of such agent to the expression product, the anti-cancer portion of said agent acts against said expression product so as to neutralize its effects in initiating, facilitating or promoting tumor formation and/or growth. In a separate embodiment of the present invention, binding of the agent to said expression product may, without more, have the effect of deterring cancer promotion, facilitation or growth, especially where the presence of said expression product is related, either intimately or only in an ancillary manner, to the development and growth of a tumor. Thus, where the presence of said expression product is essential to tumor initiation and/or growth, binding of said agent to said expression product will have the effect of negating said tumor promoting activity. In one such embodiment, said agent is an apoptosis- inducing agent that induces cell suicide, thereby killing the cancer cell and halting tumor growth..
As disclosed herein, the present invention further relates to a process for determining a cancer initiating, facilitating or suppressing gene in a cancer cell comprising determining a change in expression of a gene sequence, especially where said sequence is one selected from the group consisting of the sequences of SEQ ID NO: 1 - 8447.
Thus, the processes of the present invention take advantage of the correlation of changes in mRNA expression profiles of these signature gene sets with potential (depending on the form of cancer) changes in DNA copy number of the chromosomal regions wherein these genes are located. Of course, the precise nature of the change in mRNA expression (e.g. a signature set of genes that are up-regulated at the transcriptional level) may also indicate a change in the DNA copy number for the genomic regions in which these genes are located (e.g. an amplification of the genomic DNA region that contains the involved gene or genes).
All cancers contain chromosomal rearrangements, which typically represent translocations, amplifications, or deletions of specific regions of genomic DNA. A recurrent chromosomal rearrangement that is associated with a specific stage and type of cancer always affects a gene (or possibly genes) that play a direct and critical role in the initiation or progression of the disease. Many of the known oncogenes or tumor suppressor genes that play direct roles in cancer have either been initially identified based upon their positional cloning from a recurrent chromosomal rearrangement or have been demonstrated to fall within a rearrangement subsequent to their cloning by other methods. In all cases, such genes display amplification at both the level of DNA copy number and at the level of transcriptional expression at the mRNA level.
At least some of the genes that are contained within signature gene sets disclosed herein (SEQ ID NO: 1 - 8447) display changes in their mRNA expression profiles (depending on the precise reading frame involved) within cancer samples due, in part, to changes in their DNA copy number as a result of specific chromosomal rearrangements in those cancer cells. The utilities that follow from this are (i) that the genes contained within these signature gene sets offer a time saving shortcut to the identification of novel chromosomal rearrangements, amplifications, or deletions that are associated with cancer, and/or (ii) represent key genes affected by such chromosomal rearrangements, amplifications, or deletions and, therefore, play a key role in the initiation or progression of the disease. Genes within the signature sets that identify changes in the DNA copy number (based upon their changes in expression at the mRNA level) thus afford an entry point into other forms of diagnostic assay for the initiation, staging, or progression of cancer to be conducted in tissue samples at the DNA level (e.g. if gene X identifies a novel chromosomal amplification associated with < cancer, then that specific chromosomal region defined by gene X would serve as the basis for a diagnostic assay for cancer, where genomic DNA is extracted from tissue samples and evaluated for the presence of the specific amplification), and also the rapid positional cloning of genes that play vital and direct roles in the initiation or progression of cancer. In one embodiment of the present invention, said change in expression may be determined by determining a change in gene copy number, wherein said change in copy number is an increase in copy number or wherein said change in copy number is a decrease in copy number.
Such change in gene copy number may be determined by determining a change in expression of messenger RNA encoded by a particular gene sequence, especially where said sequence is one selected from the group consisting of the sequences of SEQ ID NO: 1 - 8447. Also in accordance with the present invention, said gene may be a cancer initiating gene, a cancer facilitating gene, or a cancer suppressing gene. In carrying out the methods of the present invention, a cancer facilitating gene is a gene that, while not directly initiating or suppressing tumor formation or growth, said gene acts, such as through the actions of its expression product, to direct, enhance, or otherwise facilitate the progress of the cancerous condition, including where such gene acts against genes, or gene expression products, that would otherwise have the effect of decreasing tumor formation and/or growth.
Thus, the present invention also provides a process for diagnosing a cancerous cell comprising determining a cancer initiating, facilitating or suppressing gene according to the above-described methods.
The present invention also relates to a process for treating cancer comprising inserting into a cancerous cell a gene construct comprising an anti-cancer gene operably linked to a promoter or enhancer element such that expression of said anti-cancer gene causes suppression of said cancer and wherein said promoter or enhancer element is a promoter or enhancer element modulating a gene sequence selected from the group consisting of the sequences of SEQ ID NO: 1 - 8447.
Thus, the signature sets or signature gene sets disclosed herein are useful in identifying genetic regulatory elements within the promoters of the genes contained within the signature sets that are specific to normal tissue and/or the corresponding cancer. In accordance with this, each signature set is a collection of genes that share a gross common pattern of transcriptional regulation in cancer vs. normal (e.g. a signature set of genes that are transcriptionally up-regulated in cancer).
In one such embodiment, analyzing and comparing the DNA sequences of the promoter regions of all the genes contained within the signature set serves to identify conserved stretches or motifs of sequences within subsets of genes that represent cis-acting elements that specifically drive a form of gene expression (e.g. increased transcriptional expression in cancer). The identification of such cis-acting regulatory elements is then available for use in driving the cancer-specific expression of suicide genes or toxins via genetic therapy using technology already well known in the art.
In separate embodiments, said anti-cancer gene is a cancer suppressor gene or encodes a polypeptide having anticancer activity, especially where said polypeptide has apoptotic activity.
In additional embodiments, the present invention such insertion of said gene construct into a cancerous cell is accomplished in vivo, for example using a viral or plasmid vector. Such methods can also be applied to in vitro uses. Thus, the methods of the present invention are readily applicable to different forms of gene therapy, either where cells are genetically modified ex vivo and then administered to a host or where the gene modification is conducted in vivo using any of a number of suitable methods involving vectors especially suitable to such therapies, such as the use of special viral vectors, including adeno-associated viruses and adenoviruses, as well as retroviruses and specially constructed plasmids to accomplish such therapies. The use of these and other vectors is well known to those skilled in the art and need not be described further. The present method also relates to a process for determining functionally related genes comprising contacting one or more gene sequences selected from the group consisting of the sequences of SEQ ID NO: 1 - 8447 with an agent that modulates expression of more than one gene in such group and thereby determining a subset of genes of said group.
In accordance with the present invention, said functionally related genes are genes modulating the same metabolic pathway or said genes are genes encoding functionally related polypeptides. In one such embodiment, said genes are genes whose expression is modulated by the same transcriptional activator or enhancer sequence, especially where said transcriptional activator or enhancer increases, or otherwise modulates, the activity of a gene sequence selected from the group consisting of SEQ ID NO: 1 - 8447.
Thus, the signature gene set disclosed herein also find use as the basis for small molecule assays for therapeutics based upon changes in expression profile. In one such embodiment, small molecule screens serve to identify changes in expression of genes within a signature set and thereby provide a tool for the identification of specific functional pathways and a means of assigning defined functions to novel genes.
In accordance with the foregoing, monitoring the transcriptional expression of the genes contained within the signature sets disclosed herein forms the basis of an assay for small molecule therapeutics. For example, in situations where a signature set of genes that are transcriptionally up- regulated in cancer cells compared to normal cells, such screens facilitate the identification of small molecules that down-regulate the expression of the genes of the signature set within cancer cells. While such therapeutics make a cancer cell "look" more normal, based upon the expression of the genes within the signature set, what actually happens when such screens are put into practice is that all genes within the signature sets do not respond identically to each small molecule within a chemical compound library. If an average signature set contains 200 different genes, for example, and the expression of all 200 genes is monitored in response to a library of some 50,000 chemical compounds, and subsets of genes within the signature set consistently change their patterns of expression in response to particular chemicals (e.g., 10 of the genes always change expression in a coordinated way, such as down-regulation of one gene within the group of 10) then it always causes the down-regulation of the other 9 specific genes as well.
Such subsets or subgroups of genes within each signature set that change their expression in a coordinated way in response to chemical compounds represent genes that are located within a common metabolic, signaling, physiological, or functional pathway so that by analyzing and identifying such subsets one can (a) assign known genes and novel genes to specific pathways and (b) identify specific functions and functional roles for novel genes that are grouped into pathways with genes for which their functions are already characterized or described. For example, one might identify a subgroup of 10 genes within a signature set (5 known genes & 5 novel genes) that change expression in a coordinated fashion and for which the 5 known genes are involved in apoptosis thereby implicating the other 5 novel genes as playing a role in apoptotic cellular processes. Therefore, the processes disclosed according to the present invention at once provide a novel means of assigning function to genes, i.e. a novel method of functional genomics, and a means for identifying chemical compounds that have potential therapeutic effects on specific cellular pathways. Such chemical compounds may have therapeutic relevance to a variety of diseases outside of cancer as well, in cases where such diseases are known or are demonstrated to involve the specific cellular pathway that is affected.
It should be cautioned that, in carrying out the procedures of the present invention as disclosed herein, any reference to particular buffers, media, reagents, cells, culture conditions and the like are not intended to be limiting, but are to be read so as to include all related materials that one of ordinary skill in the art would recognize as being of interest or value in the particular context in which that discussion is presented. For example, it is often possible to substitute one buffer system or culture medium for another and still achieve similar, if not identical, results. Those of skill in the art will have sufficient knowledge of such systems and methodologies so as to be able, without undue experimentation, to make substitutions that will optimally serve their purposes in using the methods and procedures disclosed herein.
The present invention will now be further described by way of the following non-limiting example but it should be kept clearly in mind that other and different embodiments of the methods disclosed according to the present invention will no doubt suggest themselves to those of skill in the relevant art.
EXAMPLE
SW480 cells are grown to a density of 105 cells/cm2 in Leibovitz's L-15 medium supplemented with 2 mM L-glutamine (90%) and 10% fetal bovine serum. The cells are collected after treatment with 0.25% trypsin, 0.02% EDTA at 37°C for 2 to 5 minutes. The trypsinized cells are then diluted with 30 ml growth medium and plated at a density of 50,000 cells per well in a 96 well plate (200 μl/well). The following day, cells are treated with either compound buffer alone, or compound buffer containing a chemical agent to be tested, for 24 hours. The medium is then removed, the cells lysed and the RNA recovered using the RNAeasy reagents and protocol obtained from Qiagen. RNA is quantitated and 10 ng of sample in 1 μl are added to 24 μl of Taqman reaction mix containing 1X PCR buffer, RNAsin, reverse transcriptase, nucleoside triphosphates, amplitaq gold, tween 20, glycerol, bovine serum albumin (BSA) and specific PCR primers and probes for a reference gene (18S RNA) and a test gene (Gene X). Reverse transcription is then carried out at 48°C for 30 minutes. The sample is then applied to a Perlin Elmer 7700 sequence detector and heat denatured for 10 minutes at 95°C. Amplification is performed through 40 cycles using 15 seconds annealing at 60°C followed by a 60 second extension at 72°C and 30 second denaturation at 95°C. Data files are then captured and the data analyzed with the appropriate baseline windows and thresholds.
The quantitative difference between the target and reference genes is then calculated and a relative expression value determined for all of the samples used. This procedure is then repeated for each of the target genes in a given signature, or characteristic, set and the relative expression ratios for each pair of genes is determined (i.e., a ratio of expression is determined for each target gene versus each of the other genes for which expression is measured, where each gene's absolute expression is determined relative to the reference gene for each compound, or chemical agent, to be screened). The samples are then scored and ranked according to the degree of alteration of the expression profile in the treated samples relative to the control. The overall expression of the set of genes relative to the controls, as modulated by one chemical agent relative to another, is also ascertained. Chemical agents having the most effect on a given gene, or set of genes, are considered the most anti-neoplastic.
In carrying out the methods of the invention, it is to be expected that not all cells of a given sample of suspected cancerous cells will express all, or even most, of these genes but that a substantial expression thereof in a substantial number of such cells is sufficient to warrant a determination of a cancerous, or potentially cancerous, condition. The sequences disclosed herein are presented in numerical order from SEQ ID NO: 1 to 8447 although different genes are more or less relevant to different organs and tissues and some may be up-regulated in cancer and not normal cells while other are up- regulated in normal cells but not cancerous cells. The sequences presented herein may be genomic or cDNA sequences and may also be represented as RNA sequences.

Claims

WHAT IS CLAIMED IS:
1. A process for screening for an anti-neoplastic agent comprising the steps of: (a) exposing cells to a chemical agent to be tested for antineoplastic activity, and
(b) determining a change in expression of at least one gene that includes one of the sequences of SEQ ID NOS: 1 - 8447, or a sequence that is at least 95% identical thereto,
wherein a change in expression is indicative of anti-neoplastic activity.
2. The process of claim 1 wherein expression is determined for more than one said gene.
3. The process of claim 1 wherein expression is determined for at least 5 said genes.
4. The process of claim 1 wherein expression is determined for at least 10 said genes.
5. The process of claim 1 wherein expression is determined for all said genes in a given signature gene set.
6. A process for determining the cancerous status of a test cell, comprising determining expression in said test cell of at least one gene that includes one of the nucleotide sequences selected from the sequences of SEQ ID NOS: 1 - 8447, or a nucleotide sequence that is at least 95% identical thereto, and then comparing said expression to expression of said at least one gene in at least one cell known to be non-cancerous whereby a difference in said expression indicates that said cell is cancerous.
7. The process of claim 6 wherein said expression is the expression of more than one said gene.
8. The process of claim 6 wherein said expression is the expression of at least 5 said genes.
9. The process of claim 6 wherein said expression is the expression of at least 10 said genes.
10. The process of claim 6 wherein said expression is the expression of all said genes.
11. A process for determining a cancer initiating, facilitating or suppressing gene comprising the steps of contacting a cell with a cancer modulating agent and determining a change in expression of a gene selected from the group consisting of the gene sequences of SEQ ID NO: 1 - 8447 and thereby identifying said gene as being a cancer initiating or facilitating gene.
12. The process of claim 11 wherein the gene determined by said process is an oncogene.
13. The process of claim 11 wherein the gene determined by said process is a cancer facilitating gene.
14. The process of claim 11 wherein the gene determined by said process is a cancer suppressor gene.
15. The process of claim 11 wherein said cancer modulating agent has the effect of increasing gene expression. 16. The process of claim 11 wherein said cancer modulating agent has the effect of decreasing gene expression.
17. A process for treating cancer comprising contacting a cancerous cell with an agent having activity against an expression product encoded by a gene sequence selected from the group consisting of SEQ ID NO: 1 - 8447.
18. The process of claim 17 wherein said cancerous cell is contacted in vivo.
19. The process of claim 17 wherein said agent comprises a portion having affinity for said expression product.
20. The process of claim 19 wherein said portion having affinity for said expression product is an antibody.
21. The process of claim 17 wherein said agent is an apoptosis- inducing agent.
22. A process for determining a cancer initiating, facilitating or suppressing gene in a cancer cell comprising determining a change in expression of a gene sequence selected from the group consisting of the sequences of SEQ ID NO: 1 - 8447.
23. The process of claim 22 wherein said change in expression is determined by determining a change in gene copy number.
24. The process of claim 23 wherein said change in copy number is an increase in copy number.
25. The process of claim 23 wherein said change in copy number is a decrease in copy number. 26. The process of 23 wherein said change in gene copy number is determined by determining a change in expression of messenger RNA encoded by said gene sequence.
28. The process of claim 23 wherein said gene is a cancer initiating gene.
29. The process of claim 23 wherein said gene is a cancer facilitating gene.
30. The process of claim 23 wherein said gene is a cancer suppressing gene.
31. A process for diagnosing a cancerous cell comprising determining a cancer initiating, facilitating or suppressing gene according to claim 23.
32. A process for treating cancer comprising inserting into a cancerous cell a gene construct comprising an anti-cancer gene operably linked to a promoter or enhancer element such that expression of said anti-cancer gene causes suppression of said cancer and wherein said promoter or enhancer element is a promoter or enhancer element modulating a gene sequence selected from the group consisting of the sequences of SEQ ID NO: 1 - 8447.
33. The process of claim 32 wherein said anti-cancer gene is a cancer suppressor gene.
34. The process of claim 32 wherein said anti-cancer gene encodes a polypeptide having anticancer activity.
35. The process of claim 34 wherein said polypeptide has apoptotic activity.
36. The process of claim 32 wherein said inserting into a cancerous cell is accomplished in vivo.
37. The process of claim 32 wherein said inserting into a cancerous cell further comprises use of a viral or plasmid agent and is accomplished either in vitro or in vivo.
38. The process of claim 32 wherein said cancer is selected from the group consisting of colon cancer, breast cancer, stomach cancer, lung cancer, thyroid cancer, esophageal cancer, ovarian cancer, kidney cancer, prostate cancer and pancreatic cancer.
39. The process of claim 32 wherein said cancer is of a type selected from the group consisting of adenocarcinoma, carcinoma, clear cell cancer, infiltrating ductal cancer, infiltrating lobular cancer, squamous cell carcinoma, neuroendocrine carcinoma, papillary carcinoma and Wilm's tumor.
40. A process for determining functionally related genes comprising contacting one or more gene sequences selected from the group consisting of the sequences of SEQ ID NO: 1 - 8447 with an agent that modulates expression of more than one gene in such group and thereby determining a subset of genes of said group.
41. The process of claim 40 wherein said functionally related genes are genes modulating the same metabolic pathway.
42. The process of claim 40 wherein said genes are genes encoding functionally related polypeptides.
43. The process of claim 40 wherein said all of genes are genes whose expression is modulated by the same transcription activator or enhancer sequence.
44. A method for producing a product comprising identifying an agent according to the process of claim 1 wherein said product is the data collected with respect to said agent as a result of said process and wherein said data is sufficient to convey the chemical structure and/or properties of said agent.
45. A process for screening for an anti-neoplastic agent comprising the steps of:
(a) exposing cells to a chemical agent to be tested for antineoplastic activity, and
(b) determining a change in expression of at least one gene of a signature gene set, or a sequence that is at least 95% identical thereto,
wherein a change in expression is indicative of anti-neoplastic activity.
46. The process of claim 45 wherein said change in expression is an increase in expression.
47. The process of claim 45 wherein said change in expression is a decrease in expression.
48. The process of claim 45 wherein said change in expression is a change in expression of at least 5 genes of said signature gene set.
49. The process of claim 45 wherein said change in expression is a change in expression of at least 10 genes of said signature gene set.
50. The process of claim 45 wherein said change in expression is a change in expression of at least half of the genes of said signature gene set.
PCT/US2001/010838 2000-06-05 2001-05-30 Cancer gene determination and therapeutic screening using signature gene sets WO2001094629A2 (en)

Priority Applications (5)

Application Number Priority Date Filing Date Title
AU2001264559A AU2001264559A1 (en) 2000-06-05 2001-05-30 Cancer gene determination and therapeutic screening using signature gene sets
EP01938990A EP1358349A2 (en) 2000-06-05 2001-05-30 Cancer gene determination and therapeutic screening using signature gene sets
JP2002502169A JP2004509612A (en) 2000-06-05 2001-05-30 Oncogene determination and therapeutic screening using characteristic genes
CA002411601A CA2411601A1 (en) 2000-06-05 2001-05-30 Cancer gene determination and therapeutic screening using signature gene sets
US10/843,641 US20050064454A1 (en) 2000-06-05 2004-05-11 Cancer gene determination and therapeutic screening using signature gene sets

Applications Claiming Priority (84)

Application Number Priority Date Filing Date Title
US20947300P 2000-06-05 2000-06-05
US20953100P 2000-06-05 2000-06-05
US60/209,473 2000-06-05
US60/209,531 2000-06-05
US23313300P 2000-09-18 2000-09-18
US23361700P 2000-09-18 2000-09-18
US60/233,133 2000-09-18
US60/233,617 2000-09-18
US23403400P 2000-09-20 2000-09-20
US23400900P 2000-09-20 2000-09-20
US23405200P 2000-09-20 2000-09-20
US60/234,052 2000-09-20
US60/234,009 2000-09-20
US60/234,034 2000-09-20
US23450900P 2000-09-22 2000-09-22
US23456700P 2000-09-22 2000-09-22
US60/234,509 2000-09-22
US60/234,567 2000-09-22
US23513400P 2000-09-25 2000-09-25
US23508200P 2000-09-25 2000-09-25
US23492300P 2000-09-25 2000-09-25
US23492400P 2000-09-25 2000-09-25
US23528000P 2000-09-25 2000-09-25
US23507700P 2000-09-25 2000-09-25
US60/235,082 2000-09-25
US60/235,077 2000-09-25
US60/235,280 2000-09-25
US60/235,134 2000-09-25
US60/234,923 2000-09-25
US60/234,924 2000-09-25
US23563700P 2000-09-26 2000-09-26
US23563800P 2000-09-26 2000-09-26
US60/235,638 2000-09-26
US60/235,637 2000-09-26
US23571100P 2000-09-27 2000-09-27
US23584000P 2000-09-27 2000-09-27
US23586300P 2000-09-27 2000-09-27
US23572000P 2000-09-27 2000-09-27
US60/235,840 2000-09-27
US60/235,720 2000-09-27
US60/235,711 2000-09-27
US60/235,863 2000-09-27
US23602800P 2000-09-28 2000-09-28
US23603400P 2000-09-28 2000-09-28
US23611100P 2000-09-28 2000-09-28
US23603200P 2000-09-28 2000-09-28
US23610900P 2000-09-28 2000-09-28
US23603300P 2000-09-28 2000-09-28
US60/236,034 2000-09-28
US60/236,033 2000-09-28
US60/236,028 2000-09-28
US60/236,111 2000-09-28
US60/236,109 2000-09-28
US60/236,032 2000-09-28
US23689100P 2000-09-29 2000-09-29
US23684200P 2000-09-29 2000-09-29
US60/236,891 2000-09-29
US60/236,842 2000-09-29
US23731600P 2000-10-02 2000-10-02
US23729500P 2000-10-02 2000-10-02
US23727800P 2000-10-02 2000-10-02
US23717300P 2000-10-02 2000-10-02
US23717200P 2000-10-02 2000-10-02
US23729400P 2000-10-02 2000-10-02
US60/237,295 2000-10-02
US60/237,294 2000-10-02
US60/237,278 2000-10-02
US60/237,173 2000-10-02
US60/237,316 2000-10-02
US60/237,172 2000-10-02
US23742500P 2000-10-03 2000-10-03
US23760400P 2000-10-03 2000-10-03
US23759800P 2000-10-03 2000-10-03
US23760600P 2000-10-03 2000-10-03
US23760800P 2000-10-03 2000-10-03
US60/237,604 2000-10-03
US60/237,598 2000-10-03
US60/237,606 2000-10-03
US60/237,425 2000-10-03
US60/237,608 2000-10-03
US24508400P 2000-11-01 2000-11-01
US24486700P 2000-11-01 2000-11-01
US60/245,084 2000-11-01
US60/244,867 2000-11-01

Publications (3)

Publication Number Publication Date
WO2001094629A2 true WO2001094629A2 (en) 2001-12-13
WO2001094629A8 WO2001094629A8 (en) 2002-05-16
WO2001094629A3 WO2001094629A3 (en) 2003-09-04

Family

ID=27586968

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2001/010838 WO2001094629A2 (en) 2000-06-05 2001-05-30 Cancer gene determination and therapeutic screening using signature gene sets

Country Status (5)

Country Link
EP (1) EP1358349A2 (en)
JP (1) JP2004509612A (en)
AU (1) AU2001264559A1 (en)
CA (1) CA2411601A1 (en)
WO (1) WO2001094629A2 (en)

Cited By (161)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2002004513A2 (en) * 2000-07-11 2002-01-17 Incyte Genomics, Inc. Down syndrome critical region 1-like 1 proteins
WO2002012339A2 (en) * 2000-08-03 2002-02-14 Incyte Genomics, Inc. Sequences for integrin alpha-8
WO2002016413A2 (en) * 2000-08-24 2002-02-28 Glaxosmithkline Biologicals S.A. Cripto tumour polypeptide
WO2001074900A3 (en) * 2000-03-31 2002-05-02 Aventis Pharm Prod Inc Nuclear factor kb inducing factor
WO2002044357A2 (en) * 2000-11-30 2002-06-06 Millennium Pharmaceuticals, Inc. Methods of using 18903 to treat pain and pain-related disorders
WO2002050286A2 (en) * 2000-12-20 2002-06-27 Pe Corporation (Ny) Isolated human protease proteins, nucleic acid molecules encoding human protease proteins, and uses thereof
WO2002059609A2 (en) * 2000-12-08 2002-08-01 Eos Biotechnology, Inc. Methods of diagnosing colorectal cancer and/or breast cancer, compositions, and methods of screening for colorectal cancer and/or breast cancer modulators
WO2002062958A2 (en) * 2001-02-08 2002-08-15 Tularik Inc. Prc17: an amplified cancer gene
WO2002103017A1 (en) * 2001-05-31 2002-12-27 Chiba-Prefecture Nucleic acids isolated in neuroblastoma
EP1272224A1 (en) * 2000-03-31 2003-01-08 Gene Logic, Inc. Gene expression profiles in esophageal tissue
WO2003025199A2 (en) * 2001-09-18 2003-03-27 Millennium Pharmaceuticals, Inc. Mid 4460, a human tyrosine phosphatase family member and uses therefor
WO2003028750A1 (en) * 2001-10-01 2003-04-10 Duke University Isolated grp94 ligand binding domain polypeptide and nucleic acid encoding same, and screening methods employing same
WO2003035837A2 (en) * 2001-10-23 2003-05-01 Sagres Discovery Novel compositions and methods for cancer
WO2003035857A1 (en) * 2001-10-22 2003-05-01 Bayer Healthcare Ag Regulation of human nad-dependent alpha-glycerol-3-phosphate dehydrogenase
WO2003046581A2 (en) * 2001-11-27 2003-06-05 Oxford Glycosciences (Uk) Ltd Methods for diagnosis and treatment of epithelial-derived cancers,such as colorectal cancers and kidney cancers
WO2003064451A2 (en) * 2002-02-01 2003-08-07 Beth Israel Deaconess Medical Center, Inc. MODULATION OF TYPE IIβ PHOSPHOINOSITIDE PHOSPHATE KINASE
EP1351967A2 (en) * 2000-12-12 2003-10-15 Corixa Corporation Compositions and methods for the therapy and diagnosis of lung cancer
WO2003085377A2 (en) * 2002-04-01 2003-10-16 Wyeth Novel pancortin-pablo protein interactions and methods of use thereof
EP1361433A2 (en) * 2002-04-09 2003-11-12 Kabushiki Kaisha Hayashibara Seibutsu Kagaku Kenkyujo Method for estimating therapeutic efficacy of tumor necrosis factor (TNF)
EP1365247A1 (en) * 2002-05-23 2003-11-26 Bayer Ag Diagnostics and therapeutics for diseases associated with arginine vasopressin receptor 3 (AVPR3)
EP1365244A1 (en) * 2002-05-23 2003-11-26 Bayer Ag Diagnostics and therapeutics for diseases associated with arginine vasopressin receptor 2 (AVPR2)
WO2003105758A2 (en) * 2002-06-12 2003-12-24 Avalon Pharmaceuticals, Inc. Cancer-linked gene as target for chemotherapy
WO2003105783A2 (en) * 2002-06-12 2003-12-24 Avalon Pharmaceuticals, Inc. Cancer-linked gene as target for chemotherapy
WO2004003564A2 (en) * 2002-06-26 2004-01-08 Europroteome Ag Tumour marker and the use thereof for the diagnosis and treatment of tumour diseases
WO2004007723A2 (en) * 2002-07-17 2004-01-22 Cambridge University Technical Services Limited Genes
EP1383543A1 (en) * 2001-03-23 2004-01-28 Agy Therapeutics, Inc. Use of biomolecular targets in the treatment and visualization of brain tumors
WO2004016784A1 (en) * 2002-08-06 2004-02-26 Genox Research, Inc. Protease inhibitor
WO2004022778A1 (en) * 2002-09-05 2004-03-18 Garvan Institute Of Medical Research Methods of diagnosis and prognosis of ovarian cancer
EP1402053A2 (en) * 2001-06-05 2004-03-31 Exelixis, Inc. CHDs AS MODIFIERS OF THE p53 PATHWAY AND METHODS OF USE
WO2004031411A2 (en) * 2002-09-30 2004-04-15 Oncotherapy Science, Inc. Genes and polypeptides relating to human pancreatic cancers
WO2004038411A3 (en) * 2002-10-24 2004-06-17 Evotec Neurosciences Gmbh Diagnostic and therapeutic use of ensadin-0289 gene and protein for neurodegenerative diseases
WO2004058969A1 (en) * 2002-12-24 2004-07-15 Takeda Pharmaceutical Company Limited Preventives/remedies for cancer
US6777537B1 (en) 1996-02-22 2004-08-17 Forsyth Dental Infirmary For Children Osteoclast proton pump subunit
WO2004070062A2 (en) * 2003-02-04 2004-08-19 Wyeth Compositions and methods for diagnosing and treating cancers
WO2004074510A1 (en) * 2003-02-18 2004-09-02 Garvan Institute Of Medical Research Methods of diagnosis and prognosis of pancreatic cancer
WO2004076613A2 (en) * 2003-02-26 2004-09-10 Alexander Herr Human nucleic acid sequences from carcinomas of the bladder
WO2004079013A1 (en) * 2003-03-03 2004-09-16 Arizona Board Of Regents On Behalf Of The University Of Arizona Ecto-5’-nucleotidase (cd73) used in the diagnosis and the treatment of pancreatic cancer
WO2004035082A3 (en) * 2002-10-14 2004-09-23 Develogen Ag Proteins involved in the regulation of energy homeostasis
FR2853909A1 (en) * 2003-04-16 2004-10-22 Galderma Res & Dev Using polynucleotide probes based on the DPYSL3 gene (Dihydropyrimidinase-like 3), for diagnosis of psoriasis, or predisposition, and in screening for antipsoriatic agents
EP1472376A2 (en) * 2002-01-18 2004-11-03 Millenium Pharmaceuticals, Inc. Methods and compositions for treating urological disorders using 1435, 559, 34021, 44099, 25278, 641, 260, 55089, 21407, 42032, 46656, 62553, 302, 323, 12303, 985, 13237, 13601, 18926, 318, 2058 or 6351 mo
JP2004329211A (en) * 2003-03-31 2004-11-25 Veridex Llc Colorectal cancer prognostics
WO2004104224A2 (en) * 2003-05-21 2004-12-02 F. Hoffmann-La Roche Ag Markers for lxr activation
EP1496743A2 (en) * 2002-04-05 2005-01-19 Corixa Corporation Compositions and methods for the therapy and diagnosis of lung cancer
WO2005013893A2 (en) * 2003-07-24 2005-02-17 Avalon Pharmaceuticals, Inc. Cancer related genes
WO2005014818A1 (en) 2003-08-08 2005-02-17 Perseus Proteomics Inc. Gene overexpressed in cancer
EP1510587A1 (en) * 2002-05-21 2005-03-02 Sysmex Corporation Nucleic acid amplification primers for detecting cytokeratins and examination method with the use of the primers
EP1512758A1 (en) * 2003-08-27 2005-03-09 Veridex, LLC Colorectal cancer prognostics
WO2005024055A1 (en) * 2003-09-05 2005-03-17 Garvan Institute Of Medical Research Methods of diagnosis and prognosis of ovarian cancer ii
US6887975B2 (en) 1998-06-01 2005-05-03 Agensys, Inc. Peptides derived from STEAP1
US6893818B1 (en) 1999-10-28 2005-05-17 Agensys, Inc. Gene upregulated in cancers of the prostate
WO2005054508A2 (en) * 2003-12-01 2005-06-16 Ipsogen Gene expression profiling of colon cancer by dna microarrays and correlation with survival and histoclinical parameters
WO2005062055A2 (en) * 2003-12-24 2005-07-07 Cancer Research Technology Limited Methods for detecting neoplasia and markers thereof
WO2005076005A2 (en) * 2004-01-30 2005-08-18 Medizinische Universität Wien A method for classifying a tumor cell sample based upon differential expression of at least two genes
WO2005090991A1 (en) * 2004-03-24 2005-09-29 Oncotherapy Science, Inc. Adam8 as tumor marker and therapeutic target for non-small cell lung cancer
WO2004111273A3 (en) * 2003-05-30 2005-10-06 Genomic Health Inc Gene expression markers for response to egfr inhibitor drugs
US6953658B2 (en) 2000-03-09 2005-10-11 Diadexus, Inc. Method of diagnosing, monitoring, staging, imaging and treating gastrointestinal cancer
WO2005097204A1 (en) * 2004-04-09 2005-10-20 Takeda Pharmaceutical Company Limited Preventives/remedies for cancer
EP1603514A2 (en) * 2003-01-24 2005-12-14 Bayer Pharmaceuticals Corporation Expression profiles for colon cancer and methods of use
WO2006002433A2 (en) * 2004-06-24 2006-01-05 Veridex, Llc Methods and reagents for the detection of melanoma
EP1557466A4 (en) * 2002-09-27 2006-02-08 Dainippon Sumitomo Pharma Co Tumor antigen protein and utilization thereof
WO2005090603A3 (en) * 2004-03-23 2006-03-02 Oncotherapy Science Inc Method for diagnosing non-small cell lung cancer
WO2006027693A2 (en) * 2004-09-09 2006-03-16 Exonhit Therapeutics Sa Tumor specific genes and variant rnas and uses thereof as targets for cancer therapy and diagnosis
US7041497B2 (en) 2000-03-31 2006-05-09 Aventis Pharmaceuticals Products Inc. Nuclear factor κB inducing factor
WO2006053442A1 (en) * 2004-11-22 2006-05-26 Diagnocure Inc. Calml3 a specific and sensitive target for lung cancer diagnosis, prognosis and/or theranosis
WO2006056080A1 (en) * 2004-11-29 2006-06-01 Diagnocure Inc. Gpx2 a specific and sensitive target for lung cancer diagnosis, prognosis and/or theranosis
EP1666493A1 (en) * 2000-06-02 2006-06-07 Genentech, Inc. Secreted and transmembrane polypeptides and nucleic acids ancoding the same
EP1666490A2 (en) * 2000-07-25 2006-06-07 Genentech, Inc. Secreted and transmembrane polypeptides and nucleic acids encoding the same
EP1623993A3 (en) * 1999-09-01 2006-06-07 Genetech, Inc. Secreted and transmembrane polypeptides and nucleic acids encoding the same
EP1487991A4 (en) * 2002-03-06 2006-06-14 Avalon Pharmaceuticals Cancer-linked gene as target for chemotherapy
US7063854B1 (en) 1998-09-30 2006-06-20 Corixa Corporation Composition and methods for WTI specific immunotherapy
EP1694866A2 (en) * 2003-12-12 2006-08-30 Bayer Pharmaceuticals Corporation Gene expression profiles and methods of use
US7115272B1 (en) 1998-09-30 2006-10-03 Corixa Corporation Compositions and methods for WT1 specific immunotherapy
EP1709152A2 (en) * 2003-12-15 2006-10-11 The Regents Of The University Of California Molecular signature of the pten tumor suppressor
WO2006110760A2 (en) * 2001-06-20 2006-10-19 Genentech, Inc. Compositions and methods for the diagnosis and treatment of tumor
US7144581B2 (en) 2000-10-09 2006-12-05 Corixa Corporation Compositions and methods for WT1 specific immunotherapy
EP1735461A1 (en) * 2004-04-06 2006-12-27 The Regents Of The University Of California Orphan receptor tyrosine kinase as a target in breast cancer
US7172898B2 (en) 2000-02-24 2007-02-06 Agensys, Inc. 103P2D6: tissue specific protein highly expressed in various cancers
US7189524B1 (en) 2002-11-25 2007-03-13 Amgen, Inc. Receptor ligands and methods of modulating receptors
EP1774043A2 (en) * 2004-05-28 2007-04-18 Dana-Farber Cancer Institute, Inc. Compositions, kits, and methods for identification, assessment, prevention, and therapy of cancer
WO2007048978A2 (en) * 2005-10-28 2007-05-03 Biomerieux Sa Method for detecting cancer
WO2007074341A1 (en) * 2005-12-28 2007-07-05 Randox Laboratories Ltd Detection of oesophageal cancer
EP1812794A2 (en) * 2004-10-13 2007-08-01 A & G Pharmaceutical, Inc. Autocrine growth factor receptors and methods
US7258860B2 (en) 1998-03-18 2007-08-21 Corixa Corporation Compositions and methods for the therapy and diagnosis of lung cancer
US7264841B2 (en) 2004-01-21 2007-09-04 Linda Kalustian Lester Savory gluten-free foods
EP1828237A1 (en) * 2004-12-22 2007-09-05 Kim, Hyun-Kee Human cancer suppressor gene, protein encoded therein, expression vector containing the same, and cell transformed by the vector
US7271240B2 (en) 2001-03-14 2007-09-18 Agensys, Inc. 125P5C8: a tissue specific protein highly expressed in various cancers
US7291719B2 (en) 2000-07-25 2007-11-06 Genentech, Inc. PRO4332 antibodies
JP2007531500A (en) * 2003-07-17 2007-11-08 パシフィック エッジ バイオテクノロジー リミティド Gastric cancer detection marker
WO2007128984A2 (en) * 2006-04-06 2007-11-15 Randox Laboratories Ltd Breast cancer makers
US7319006B2 (en) 1998-06-01 2008-01-15 Genentech, Inc. Serpentine transmembrane antigens expressed in human cancers and uses thereof
US7323181B2 (en) 1998-09-30 2008-01-29 Corixa Corporation Compositions and methods for WT1 specific immunotherapy
US7329410B1 (en) 1998-09-30 2008-02-12 Corixa Corporation Compositions and method for WT1 specific immunotherapy
US7329502B2 (en) 2002-04-25 2008-02-12 The United States Of America As Represented By The Department Of Health And Human Services ZAP-70 expression as a marker for chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL)
WO2008024009A1 (en) * 2006-08-15 2008-02-28 Institut Molekulyarnoi Genetiki Rossiiskoi Akademii Nauk (Img Ran) Transcriptional level of a timp3 gene in the form of a diagnosis marker of a non-small cell carcinoma of lung
EP1860186A3 (en) * 2003-03-10 2008-03-12 Japan Science and Technology Corporation Method for distinguishing mesenchymal stem cells using different markers
US7358351B2 (en) 2000-08-02 2008-04-15 The Johns Hopkins University Endothelial cell expression patterns
WO2008045133A2 (en) * 2006-03-03 2008-04-17 Veridex, Llc Molecular assay to predict recurrence of dukes' b colon cancer
US7390882B2 (en) 2001-06-20 2008-06-24 Genentech, Inc. Compositions and methods for the diagnosis and treatment of tumor
US7425624B1 (en) * 2003-01-21 2008-09-16 Mayo Foundation For Medical Education And Research Sulfotransferase 1A3 sequence variants
WO2008151110A2 (en) * 2007-06-01 2008-12-11 The University Of North Carolina At Chapel Hill Molecular diagnosis and typing of lung cancer variants
US7482129B2 (en) * 2004-05-04 2009-01-27 Institute Of Virology, Slovak Academy Of Sciences MN/CA IX/CA9 and Renal Cancer Prognosis
EP2021034A2 (en) * 2006-04-28 2009-02-11 Inis Biotech LLC An isolated dna fragment of the human a33 promoter and its use to control the expression of a heterologous gene in tumor cells
US7491390B2 (en) 2004-10-15 2009-02-17 Seattle Genetics, Inc. Anti-CD70 antibody and its use for the treatment and prevention of cancer and immune disorders
WO2009021680A1 (en) * 2007-08-14 2009-02-19 F. Hoffmann-La Roche Ag Predictive marker for egfr inhibitor treatment
US7494646B2 (en) 2001-09-06 2009-02-24 Agensys, Inc. Antibodies and molecules derived therefrom that bind to STEAP-1 proteins
US7504222B2 (en) 2001-10-31 2009-03-17 Millennium Pharmaceuticals, Inc. Compositions, kits, and methods for identification, assessment, prevention, and therapy of breast cancer
EP1871793A4 (en) * 2005-03-30 2009-04-22 Kim Hyun Kee Human protooncogene and protein encoded by same
EP2052739A1 (en) * 2006-08-16 2009-04-29 Forerunner Pharma Research Co., Ltd. Cancer therapeutic agent comprising ligand for neuromedin u receptor 2 (fm4) molecule as active ingredient
WO2009052567A1 (en) * 2007-10-23 2009-04-30 Clinical Genomics Pty. Ltd. A method of diagnosing neoplasms - ii
US7553494B2 (en) 2001-08-24 2009-06-30 Corixa Corporation WT1 fusion proteins
WO2008154249A3 (en) * 2007-06-08 2009-07-16 Genentech Inc Gene expression markers of tumor resistance to her2 inhibitor treatment
WO2009101620A1 (en) * 2008-02-11 2009-08-20 Hadasit Medical Research Services & Development Limited Colon cancer associated transcript 1 (ccat1) as a cancer marker
US7579160B2 (en) 1998-03-18 2009-08-25 Corixa Corporation Methods for the detection of cervical cancer
US7598355B2 (en) 2000-03-24 2009-10-06 Duke University Characterization of GRP94-ligand interactions and purification, screening, and therapeutic methods relating thereto
US7604799B2 (en) 2003-06-06 2009-10-20 Medimmune, Llc EphA4 Antibodies
US7641903B2 (en) 2004-10-15 2010-01-05 Seattle Genetics, Inc. Anti-CD70 antibody and its use for the treatment and prevention of cancer and immune disorders
US7645441B2 (en) 2000-12-22 2010-01-12 Sagres Discovery Inc. Compositions and methods in cancer associated with altered expression of PRLR
US7662387B2 (en) 2003-02-20 2010-02-16 Seattle Genetics Anti-cd70 antibody-drug conjugates and their use for the treatment of cancer and immune disorders
WO2008114262A3 (en) * 2007-03-21 2010-02-25 Quark Pharmaceuticals, Inc. Oligoribonucleotide inhibitors of nrf2 and methods of use thereof for treatment of cancer
US7696336B2 (en) 2002-08-16 2010-04-13 Agensys, Inc. Nucleic acids and corresponding proteins entitled 251P5G2 useful in treatment and detection of cancer
US7700274B2 (en) 2000-12-22 2010-04-20 Sagres Discovery, Inc. Compositions and methods in cancer associated with altered expression of KCNJ9
US7700757B2 (en) 2003-04-02 2010-04-20 Giuliani Internaitonal Limited Antisense oligonucleotides (ODN) against Smad7 and uses in medical field thereof
US7736654B2 (en) 2001-04-10 2010-06-15 Agensys, Inc. Nucleic acids and corresponding proteins useful in the detection and treatment of various cancers
US7749977B2 (en) 1997-11-12 2010-07-06 Quark Pharmaceuticals, Inc. Therapeutic modulation of the Fas pathway
EP2177614A3 (en) * 2005-05-02 2010-08-11 Toray Industries, Inc. Composition and method for diagnosing esophageal cancer and metastasis of esophageal cancer
US7820447B2 (en) 2000-12-22 2010-10-26 Sagres Discovery Inc. Compositions and methods for cancer
AU2004264952B2 (en) * 2003-08-14 2010-12-16 Exelixis, Inc. PRKCs as modifiers of the beta catenin pathway and methods of use
EP2269628A2 (en) 2002-05-29 2011-01-05 DeveloGen Aktiengesellschaft Pancreas-specific proteins
EP2270501A3 (en) * 2002-09-30 2011-01-19 Oncotherapy Science, Inc. Method for diagnosing non-small cell lung cancers
WO2011009036A1 (en) * 2009-07-16 2011-01-20 Soymeds, Inc. Soybean derived human thyroglobulin, methods of producing and applications thereof
WO2011013729A1 (en) 2009-07-30 2011-02-03 オンコセラピー・サイエンス株式会社 Fused imidazole derivative having ttk inhibitory action
US7884179B2 (en) 2001-09-06 2011-02-08 Agensys, Inc. Nucleic acid and corresponding protein entitled STEAP-1 useful in treatment and detection of cancer
US7892730B2 (en) 2000-12-22 2011-02-22 Sagres Discovery, Inc. Compositions and methods for cancer
US7901693B2 (en) 1998-09-30 2011-03-08 Corixa Corporation Compositions and methods for WT1 specific immunotherapy
EP2267158A3 (en) * 2004-05-11 2011-04-06 Ganymed Pharmaceuticals AG Identification of surface-associated Antigenes used for the diagnosis and therapy of tumours
US7947459B2 (en) 1998-06-01 2011-05-24 Agensys, Inc. Serpentine transmembrane antigens expressed in human cancers and uses thereof
EP2333112A2 (en) 2004-02-20 2011-06-15 Veridex, LLC Breast cancer prognostics
US8008442B2 (en) 2004-04-22 2011-08-30 Agensys, Inc. Antibodies and molecules derived therefrom that bind to STEAP-1 proteins
US8067546B2 (en) 2005-04-19 2011-11-29 Seattle Genetics, Inc. Humanized anti-CD70 binding agents and uses thereof
US8211434B2 (en) 2008-11-26 2012-07-03 Allergan, Inc. KLK-13 antibody inhibitor for treating dry eye
US8337838B2 (en) 2004-10-15 2012-12-25 Seattle Genetics, Inc. Anti-CD70 antibody and its use for the treatment and prevention of cancer and immune disorders
EP2518166A3 (en) * 2005-05-20 2013-01-09 Veridex, LLC Thyroid fine needle aspiration molecular assay
US20130023441A1 (en) * 2004-06-04 2013-01-24 Biotheranostics, Inc. Identification of Tumors
US8436147B2 (en) 2006-10-27 2013-05-07 Genentech, Inc. Antibodies and immunoconjugates and uses therefor
US8535914B2 (en) * 2005-01-21 2013-09-17 Canon Kabushiki Kaisha Probe, probe set and information acquisition method using the same
US8637642B2 (en) 2010-09-29 2014-01-28 Seattle Genetics, Inc. Antibody drug conjugates (ADC) that bind to 191P4D12 proteins
US8647826B2 (en) 2001-03-14 2014-02-11 Agensys, Inc. Nucleic acid and corresponding protein entitled 125P5C8 useful in treatment and detection of cancer
US8663642B2 (en) 2003-02-20 2014-03-04 Seattle Genetics, Inc. Anti-CD70 antibody-drug conjugates and their use for the treatment and prevention of cancer and immune disorders
US8716021B2 (en) 2005-09-07 2014-05-06 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Use of replicators to prevent gene silencing
AU2012200098B2 (en) * 2004-05-11 2014-05-08 Ganymed Pharmaceuticals Ag Identification of surface-associated antigens for tumour diagnosis and therapy
US9120854B2 (en) 2008-04-11 2015-09-01 Seattle Genetics, Inc. Detection and treatment of pancreatic, ovarian and other cancers
US9260499B2 (en) 2008-10-20 2016-02-16 Sapporo Medical University Tumor antigen peptide and use thereof
WO2016083360A1 (en) * 2014-11-25 2016-06-02 Ait Austrian Institute Of Technology Gmbh Diagnosis of lung cancer
AU2014208220B2 (en) * 2004-05-11 2016-08-04 Ganymed Pharmaceuticals Ag Identification of surface-associated antigens for tumor diagnosis and therapy
US9498540B2 (en) 2013-03-15 2016-11-22 Novartis Ag Cell proliferation inhibitors and conjugates thereof
US9670553B2 (en) 2004-06-04 2017-06-06 Biotheranostics, Inc. Determining tumor origin
JP2021003136A (en) * 2015-05-15 2021-01-14 国立大学法人高知大学 Pancreatic cancer diagnostic kit
US11180571B2 (en) 2017-04-03 2021-11-23 Hoffmann-La Roche Inc. Antibodies binding to STEAP-1
US11319526B2 (en) 2008-05-02 2022-05-03 Seagen Inc. Methods and compositions for making antibodies and antibody derivatives with reduced core fucosylation
US11430544B2 (en) 2005-06-03 2022-08-30 Biotheranostics, Inc. Identification of tumors and tissues
US11820827B2 (en) 2019-12-30 2023-11-21 Seagen Inc. Methods of treating myelodysplastic syndrome and acute myeloid leukemia with nonfucosylated anti-CD70 antibodies

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2006174731A (en) * 2004-12-21 2006-07-06 Seikagaku Kogyo Co Ltd Translocation agent and method for detecting canceration of tissue

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1995019369A1 (en) * 1994-01-14 1995-07-20 Vanderbilt University Method for detection and treatment of breast cancer
US5882874A (en) * 1998-02-27 1999-03-16 The Trustees Of Columbia University In The City Of New York Reciprocal subtraction differential display
WO1999050278A1 (en) * 1998-03-31 1999-10-07 Genzyme Corporation Compositions and methods for the identification of lung tumor cells

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1995019369A1 (en) * 1994-01-14 1995-07-20 Vanderbilt University Method for detection and treatment of breast cancer
US5882874A (en) * 1998-02-27 1999-03-16 The Trustees Of Columbia University In The City Of New York Reciprocal subtraction differential display
WO1999050278A1 (en) * 1998-03-31 1999-10-07 Genzyme Corporation Compositions and methods for the identification of lung tumor cells

Non-Patent Citations (6)

* Cited by examiner, † Cited by third party
Title
CHENG L ET AL: "Characterisations of taxol-induced apoptosis and altered gene expression in human breast cancer cells." CELLULAR PHARMACOLOGY, vol. 2, no. 6, 1995, pages 249-257, XP008013734 ISSN: 1351-3214 *
DATABASE EBI [Online] 3 August 1996 (1996-08-03) HILLIER, L. ET AL.: "ze23c03.s1 Soares fetal heart, H. sapiens cDNA clone, mRNA sequence;" retrieved from EMBL Database accession no. AA011199 XP002230815 *
HESS J ET AL: "Application of differential cDNA screening techniques to the identification of unique gene expression in tumours and lymphocytes" CURRENT OPINION IN IMMUNOLOGY, CURRENT BIOLOGY LTD, XX, vol. 10, no. 2, April 1998 (1998-04), pages 125-130, XP004327175 ISSN: 0952-7915 *
KURDISTANI SIAVASH K ET AL: "Inhibition of tumor cell growth by RTP/rit42 and its responsiveness to p53 and DNA damage." CANCER RESEARCH, vol. 58, no. 19, 1 October 1998 (1998-10-01), pages 4439-4444, XP001109678 ISSN: 0008-5472 *
SIAVOSHIAN S ET AL: "Subtractive hybridization and differential screening identified two genes differentially expressed after induction of in vitro (atypical) terminal differentiation in the NSCLC-N6 cell line by a marine substance (bistramide K)." ANTICANCER RESEARCH., vol. 19, no. 6b, November 1999 (1999-11), pages 5361-5366, XP008013799 ISSN: 0250-7005 *
VIETOR I ET AL: "In search of differentially expressed genes and proteins" BIOCHIMICA ET BIOPHYSICA ACTA. MOLECULAR CELL RESEARCH, ELSEVIER SCIENCE PUBLISHERS, AMSTERDAM, NL, vol. 1359, no. 3, 12 December 1997 (1997-12-12), pages 187-199, XP004277797 ISSN: 0167-4889 *

Cited By (347)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6777537B1 (en) 1996-02-22 2004-08-17 Forsyth Dental Infirmary For Children Osteoclast proton pump subunit
US7749977B2 (en) 1997-11-12 2010-07-06 Quark Pharmaceuticals, Inc. Therapeutic modulation of the Fas pathway
US7579160B2 (en) 1998-03-18 2009-08-25 Corixa Corporation Methods for the detection of cervical cancer
US7585506B2 (en) 1998-03-18 2009-09-08 Corixa Corporation Compositions and methods for the therapy and diagnosis of lung cancer
US7258860B2 (en) 1998-03-18 2007-08-21 Corixa Corporation Compositions and methods for the therapy and diagnosis of lung cancer
US7727533B2 (en) 1998-06-01 2010-06-01 Genentech, Inc. Serpentine transmembrane antigens expressed in human cancers and uses thereof
US6887975B2 (en) 1998-06-01 2005-05-03 Agensys, Inc. Peptides derived from STEAP1
US7575749B2 (en) 1998-06-01 2009-08-18 Agensys, Inc. Serpentine transmembrane antigens expressed in human cancers and uses thereof
US7485299B2 (en) 1998-06-01 2009-02-03 Agensys, Inc. Serpentine transmembrane antigens expressed in human cancers and uses thereof
US7319006B2 (en) 1998-06-01 2008-01-15 Genentech, Inc. Serpentine transmembrane antigens expressed in human cancers and uses thereof
US7947459B2 (en) 1998-06-01 2011-05-24 Agensys, Inc. Serpentine transmembrane antigens expressed in human cancers and uses thereof
US7662386B2 (en) 1998-09-30 2010-02-16 Corixa Corporation Compositions and methods for WT1 specific immunotherapy
US7063854B1 (en) 1998-09-30 2006-06-20 Corixa Corporation Composition and methods for WTI specific immunotherapy
US7323181B2 (en) 1998-09-30 2008-01-29 Corixa Corporation Compositions and methods for WT1 specific immunotherapy
US7115272B1 (en) 1998-09-30 2006-10-03 Corixa Corporation Compositions and methods for WT1 specific immunotherapy
US7901693B2 (en) 1998-09-30 2011-03-08 Corixa Corporation Compositions and methods for WT1 specific immunotherapy
US7329410B1 (en) 1998-09-30 2008-02-12 Corixa Corporation Compositions and method for WT1 specific immunotherapy
US7655249B2 (en) 1998-09-30 2010-02-02 Corixa Corporation Compositions and methods for WT1 specific immunotherapy
US7368119B2 (en) 1998-09-30 2008-05-06 Corixa Corporation Compositions and methods for WT1 specific immunotherapy
US8053551B2 (en) 1999-06-01 2011-11-08 Agensys, Inc. Serpentine transmembrane antigens expressed in human cancers and uses therefor
US8241626B2 (en) 1999-06-01 2012-08-14 Agensys, Inc. Serpentine transmembrane antigens expressed in human cancers and uses thereof
EP1623993A3 (en) * 1999-09-01 2006-06-07 Genetech, Inc. Secreted and transmembrane polypeptides and nucleic acids encoding the same
US7771968B2 (en) 1999-10-28 2010-08-10 Agensys, Inc. Gene upregulated in cancers of the prostate
US6893818B1 (en) 1999-10-28 2005-05-17 Agensys, Inc. Gene upregulated in cancers of the prostate
US7928212B2 (en) 1999-10-28 2011-04-19 Agensys, Inc. Gene upregulated in cancers of the prostate
US7749505B2 (en) 1999-12-17 2010-07-06 Corixa Corporation Compositions and methods for the therapy and diagnosis of lung cancer
US7199220B2 (en) 2000-02-24 2007-04-03 Agensys, Inc. 103P2D6: tissue specific protein highly expressed in various cancers
US7172898B2 (en) 2000-02-24 2007-02-06 Agensys, Inc. 103P2D6: tissue specific protein highly expressed in various cancers
US6953658B2 (en) 2000-03-09 2005-10-11 Diadexus, Inc. Method of diagnosing, monitoring, staging, imaging and treating gastrointestinal cancer
US7235649B2 (en) 2000-03-24 2007-06-26 Duke University Isolated GRP94 ligand binding domain polypeptide and nucleic acid encoding same, and screening methods employing same
US7598355B2 (en) 2000-03-24 2009-10-06 Duke University Characterization of GRP94-ligand interactions and purification, screening, and therapeutic methods relating thereto
WO2001074900A3 (en) * 2000-03-31 2002-05-02 Aventis Pharm Prod Inc Nuclear factor kb inducing factor
EP1272224A1 (en) * 2000-03-31 2003-01-08 Gene Logic, Inc. Gene expression profiles in esophageal tissue
US8623831B2 (en) 2000-03-31 2014-01-07 Aventis Pharmaceuticals Inc. Nuclear factor κB inducing factor
US8642739B2 (en) 2000-03-31 2014-02-04 Aventis Pharmaceuticals Inc. Nuclear factor κB inducing factor
EP1272224A4 (en) * 2000-03-31 2004-09-29 Gene Logic Inc Gene expression profiles in esophageal tissue
US7972844B2 (en) 2000-03-31 2011-07-05 Aventis Pharmaceuticals Inc. Nuclear factor κB inducing factor
US7041497B2 (en) 2000-03-31 2006-05-09 Aventis Pharmaceuticals Products Inc. Nuclear factor κB inducing factor
EP1666493A1 (en) * 2000-06-02 2006-06-07 Genentech, Inc. Secreted and transmembrane polypeptides and nucleic acids ancoding the same
WO2002004513A3 (en) * 2000-07-11 2003-04-24 Incyte Genomics Inc Down syndrome critical region 1-like 1 proteins
WO2002004513A2 (en) * 2000-07-11 2002-01-17 Incyte Genomics, Inc. Down syndrome critical region 1-like 1 proteins
US7291719B2 (en) 2000-07-25 2007-11-06 Genentech, Inc. PRO4332 antibodies
EP1666490A2 (en) * 2000-07-25 2006-06-07 Genentech, Inc. Secreted and transmembrane polypeptides and nucleic acids encoding the same
US7335731B2 (en) 2000-07-25 2008-02-26 Genentech, Inc. PRO4332 polypeptides
EP1666490A3 (en) * 2000-07-25 2006-11-02 Genentech, Inc. Secreted and transmembrane polypeptides and nucleic acids encoding the same
US7358351B2 (en) 2000-08-02 2008-04-15 The Johns Hopkins University Endothelial cell expression patterns
US7402660B2 (en) 2000-08-02 2008-07-22 The Johns Hopkins University Endothelial cell expression patterns
WO2002012339A2 (en) * 2000-08-03 2002-02-14 Incyte Genomics, Inc. Sequences for integrin alpha-8
WO2002012339A3 (en) * 2000-08-03 2002-06-13 Incyte Genomics Inc Sequences for integrin alpha-8
US7439320B2 (en) 2000-08-24 2008-10-21 Glaxosmith Kline Biologicals S.A. Cripto tumour polypeptide
WO2002016413A2 (en) * 2000-08-24 2002-02-28 Glaxosmithkline Biologicals S.A. Cripto tumour polypeptide
WO2002016413A3 (en) * 2000-08-24 2002-12-05 Smithkline Beecham Biolog Cripto tumour polypeptide
US7144581B2 (en) 2000-10-09 2006-12-05 Corixa Corporation Compositions and methods for WT1 specific immunotherapy
WO2002044357A2 (en) * 2000-11-30 2002-06-06 Millennium Pharmaceuticals, Inc. Methods of using 18903 to treat pain and pain-related disorders
US7081344B2 (en) 2000-11-30 2006-07-25 Millennium Pharmaceuticals, Inc. Methods for screening compounds that bind human COE-2
WO2002044357A3 (en) * 2000-11-30 2003-02-13 Millennium Pharm Inc Methods of using 18903 to treat pain and pain-related disorders
WO2002059609A2 (en) * 2000-12-08 2002-08-01 Eos Biotechnology, Inc. Methods of diagnosing colorectal cancer and/or breast cancer, compositions, and methods of screening for colorectal cancer and/or breast cancer modulators
WO2002059609A3 (en) * 2000-12-08 2004-02-12 Eos Biotechnology Inc Methods of diagnosing colorectal cancer and/or breast cancer, compositions, and methods of screening for colorectal cancer and/or breast cancer modulators
EP1351967A2 (en) * 2000-12-12 2003-10-15 Corixa Corporation Compositions and methods for the therapy and diagnosis of lung cancer
EP1351967A4 (en) * 2000-12-12 2004-12-22 Corixa Corp Compositions and methods for the therapy and diagnosis of lung cancer
WO2002050286A3 (en) * 2000-12-20 2003-03-13 Pe Corp Ny Isolated human protease proteins, nucleic acid molecules encoding human protease proteins, and uses thereof
WO2002050286A2 (en) * 2000-12-20 2002-06-27 Pe Corporation (Ny) Isolated human protease proteins, nucleic acid molecules encoding human protease proteins, and uses thereof
US7700274B2 (en) 2000-12-22 2010-04-20 Sagres Discovery, Inc. Compositions and methods in cancer associated with altered expression of KCNJ9
US7820447B2 (en) 2000-12-22 2010-10-26 Sagres Discovery Inc. Compositions and methods for cancer
US7645441B2 (en) 2000-12-22 2010-01-12 Sagres Discovery Inc. Compositions and methods in cancer associated with altered expression of PRLR
US7892730B2 (en) 2000-12-22 2011-02-22 Sagres Discovery, Inc. Compositions and methods for cancer
WO2002062958A2 (en) * 2001-02-08 2002-08-15 Tularik Inc. Prc17: an amplified cancer gene
WO2002062958A3 (en) * 2001-02-08 2003-04-10 Tularik Inc Prc17: an amplified cancer gene
US7488479B2 (en) 2001-03-14 2009-02-10 Agensys, Inc. Nucleic acid and corresponding protein entitled 125P5C8 useful in treatment and detection of cancer
US7759474B2 (en) 2001-03-14 2010-07-20 Agensys, Inc. Nucleic acid and corresponding protein entitled 125P5C8 useful in treatment and detection of cancer
US8647826B2 (en) 2001-03-14 2014-02-11 Agensys, Inc. Nucleic acid and corresponding protein entitled 125P5C8 useful in treatment and detection of cancer
US7968090B2 (en) 2001-03-14 2011-06-28 Agensys, Inc. Nucleic acids and corresponding proteins entitled 191P4D12(b) useful in treatment and detection of cancer
US7834156B2 (en) 2001-03-14 2010-11-16 Agensys, Inc. 125P5C8: tissue specific protein highly expressed in various cancers
US7271240B2 (en) 2001-03-14 2007-09-18 Agensys, Inc. 125P5C8: a tissue specific protein highly expressed in various cancers
US7928196B2 (en) 2001-03-14 2011-04-19 Agensys, Inc. Nucleic acid and corresponding protein entitled 125P5C8 useful in treatment and detection of cancer
EP1383543A1 (en) * 2001-03-23 2004-01-28 Agy Therapeutics, Inc. Use of biomolecular targets in the treatment and visualization of brain tumors
EP1383543A4 (en) * 2001-03-23 2006-06-21 Agy Therapeutics Inc Use of biomolecular targets in the treatment and visualization of brain tumors
US7736654B2 (en) 2001-04-10 2010-06-15 Agensys, Inc. Nucleic acids and corresponding proteins useful in the detection and treatment of various cancers
WO2002103017A1 (en) * 2001-05-31 2002-12-27 Chiba-Prefecture Nucleic acids isolated in neuroblastoma
EP1402053A2 (en) * 2001-06-05 2004-03-31 Exelixis, Inc. CHDs AS MODIFIERS OF THE p53 PATHWAY AND METHODS OF USE
EP1402053A4 (en) * 2001-06-05 2005-05-11 Exelixis Inc CHDs AS MODIFIERS OF THE p53 PATHWAY AND METHODS OF USE
EP2000482A1 (en) * 2001-06-20 2008-12-10 Genentech, Inc. Compositions and methods for the diagnosis and treatment of tumor
US8728480B2 (en) 2001-06-20 2014-05-20 Genetech, Inc. Methods for the treatment of tumors expressing TAT123 or naturally occurring variants thereof
US8398982B2 (en) 2001-06-20 2013-03-19 Genentech, Inc. Compositions and methods for the diagnosis and treatment of tumor
WO2006110760A2 (en) * 2001-06-20 2006-10-19 Genentech, Inc. Compositions and methods for the diagnosis and treatment of tumor
US7390882B2 (en) 2001-06-20 2008-06-24 Genentech, Inc. Compositions and methods for the diagnosis and treatment of tumor
WO2006110760A3 (en) * 2001-06-20 2007-03-08 Genentech Inc Compositions and methods for the diagnosis and treatment of tumor
US7547768B2 (en) 2001-06-20 2009-06-16 Genentech, Inc. Anti-TAT 113 antibodies
US8278042B2 (en) 2001-06-20 2012-10-02 Genentech, Inc. Compositions and methods for the diagnosis and treatment of tumor
US7915393B2 (en) 2001-08-24 2011-03-29 Corixa Corporation Compositions and methods for WT1 specific immunotherapy
US7553494B2 (en) 2001-08-24 2009-06-30 Corixa Corporation WT1 fusion proteins
US7947276B2 (en) 2001-09-06 2011-05-24 Agensys, Inc. Antibodies and molecules derived therefrom that bind to STEAP-1 proteins
US7494646B2 (en) 2001-09-06 2009-02-24 Agensys, Inc. Antibodies and molecules derived therefrom that bind to STEAP-1 proteins
US7884179B2 (en) 2001-09-06 2011-02-08 Agensys, Inc. Nucleic acid and corresponding protein entitled STEAP-1 useful in treatment and detection of cancer
US7939503B2 (en) 2001-09-06 2011-05-10 Agensys, Inc. Reduction of cell-cell communication in prostate cancer using STEAP-1 siRNA
US8013135B2 (en) 2001-09-06 2011-09-06 Agensys, Inc. Antibodies and molecules derived therefrom that bind to STEAP-1 proteins
US9029516B2 (en) 2001-09-06 2015-05-12 Agensys, Inc. Antibodies and molecules derived therefrom that bind to STEAP-1 proteins
US7157240B2 (en) 2001-09-18 2007-01-02 Bayer Healthcare Ag MID 4460, a human tyrosine phosphatase family member and uses therefor
WO2003025199A3 (en) * 2001-09-18 2003-10-30 Millennium Pharm Inc Mid 4460, a human tyrosine phosphatase family member and uses therefor
WO2003025199A2 (en) * 2001-09-18 2003-03-27 Millennium Pharmaceuticals, Inc. Mid 4460, a human tyrosine phosphatase family member and uses therefor
WO2003028750A1 (en) * 2001-10-01 2003-04-10 Duke University Isolated grp94 ligand binding domain polypeptide and nucleic acid encoding same, and screening methods employing same
WO2003035857A1 (en) * 2001-10-22 2003-05-01 Bayer Healthcare Ag Regulation of human nad-dependent alpha-glycerol-3-phosphate dehydrogenase
WO2003035837A2 (en) * 2001-10-23 2003-05-01 Sagres Discovery Novel compositions and methods for cancer
WO2003035837A3 (en) * 2001-10-23 2004-02-26 Sagres Discovery Novel compositions and methods for cancer
US7504222B2 (en) 2001-10-31 2009-03-17 Millennium Pharmaceuticals, Inc. Compositions, kits, and methods for identification, assessment, prevention, and therapy of breast cancer
WO2003046581A2 (en) * 2001-11-27 2003-06-05 Oxford Glycosciences (Uk) Ltd Methods for diagnosis and treatment of epithelial-derived cancers,such as colorectal cancers and kidney cancers
AU2002343109B2 (en) * 2001-11-27 2008-06-12 Ucb Pharma S.A. Methods for diagnosis and treatment of epithelial-derived cancers, such as colorectal cancers and kidney cancers
WO2003046581A3 (en) * 2001-11-27 2004-04-08 Oxford Glycosciences Uk Ltd Methods for diagnosis and treatment of epithelial-derived cancers,such as colorectal cancers and kidney cancers
EP1472376A4 (en) * 2002-01-18 2007-03-21 Millennium Pharm Inc Methods and compositions for treating urological disorders using 1435, 559, 34021, 44099, 25278, 641, 260, 55089, 21407, 42032, 46656, 62553, 302, 323, 12303, 985, 13237, 13601, 18926, 318, 2058 or 6351 mo
EP1472376A2 (en) * 2002-01-18 2004-11-03 Millenium Pharmaceuticals, Inc. Methods and compositions for treating urological disorders using 1435, 559, 34021, 44099, 25278, 641, 260, 55089, 21407, 42032, 46656, 62553, 302, 323, 12303, 985, 13237, 13601, 18926, 318, 2058 or 6351 mo
WO2003064451A2 (en) * 2002-02-01 2003-08-07 Beth Israel Deaconess Medical Center, Inc. MODULATION OF TYPE IIβ PHOSPHOINOSITIDE PHOSPHATE KINASE
WO2003064451A3 (en) * 2002-02-01 2003-09-04 Beth Israel Hospital MODULATION OF TYPE IIβ PHOSPHOINOSITIDE PHOSPHATE KINASE
EP1487991A4 (en) * 2002-03-06 2006-06-14 Avalon Pharmaceuticals Cancer-linked gene as target for chemotherapy
WO2003085377A3 (en) * 2002-04-01 2004-12-02 Wyeth Corp Novel pancortin-pablo protein interactions and methods of use thereof
WO2003085377A2 (en) * 2002-04-01 2003-10-16 Wyeth Novel pancortin-pablo protein interactions and methods of use thereof
EP1496743A2 (en) * 2002-04-05 2005-01-19 Corixa Corporation Compositions and methods for the therapy and diagnosis of lung cancer
EP1496743A4 (en) * 2002-04-05 2006-06-21 Corixa Corp Compositions and methods for the therapy and diagnosis of lung cancer
EP1361433A3 (en) * 2002-04-09 2005-02-23 Kabushiki Kaisha Hayashibara Seibutsu Kagaku Kenkyujo Method for estimating therapeutic efficacy of tumor necrosis factor (TNF)
EP1361433A2 (en) * 2002-04-09 2003-11-12 Kabushiki Kaisha Hayashibara Seibutsu Kagaku Kenkyujo Method for estimating therapeutic efficacy of tumor necrosis factor (TNF)
US7981610B2 (en) 2002-04-25 2011-07-19 The United States Of America As Represented By The Department Of Health And Human Services ZAP-70 expression as a marker for chronic lymphocytic leukemia / small lymphocytic lymphoma (CLL/SLL)
US8748114B2 (en) 2002-04-25 2014-06-10 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services ZAP-70 expression as a marker for chronic lymphocytic leukemia / small lymphocytic lymphoma (CLL/SLL)
US7329502B2 (en) 2002-04-25 2008-02-12 The United States Of America As Represented By The Department Of Health And Human Services ZAP-70 expression as a marker for chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL)
EP1510587A1 (en) * 2002-05-21 2005-03-02 Sysmex Corporation Nucleic acid amplification primers for detecting cytokeratins and examination method with the use of the primers
EP1510587A4 (en) * 2002-05-21 2007-11-14 Sysmex Corp Nucleic acid amplification primers for detecting cytokeratins and examination method with the use of the primers
US8076080B2 (en) 2002-05-21 2011-12-13 Sysmex Corporation Nucleic acid amplification primers for detecting cytokeratins and examination method with the use of the primers
EP1365247A1 (en) * 2002-05-23 2003-11-26 Bayer Ag Diagnostics and therapeutics for diseases associated with arginine vasopressin receptor 3 (AVPR3)
EP1365244A1 (en) * 2002-05-23 2003-11-26 Bayer Ag Diagnostics and therapeutics for diseases associated with arginine vasopressin receptor 2 (AVPR2)
EP2275118A2 (en) 2002-05-29 2011-01-19 DeveloGen Aktiengesellschaft Pancreas-specific proteins
EP2269628A2 (en) 2002-05-29 2011-01-05 DeveloGen Aktiengesellschaft Pancreas-specific proteins
WO2003105783A2 (en) * 2002-06-12 2003-12-24 Avalon Pharmaceuticals, Inc. Cancer-linked gene as target for chemotherapy
WO2003105758A2 (en) * 2002-06-12 2003-12-24 Avalon Pharmaceuticals, Inc. Cancer-linked gene as target for chemotherapy
WO2003105783A3 (en) * 2002-06-12 2006-03-30 Avalon Pharmaceuticals Cancer-linked gene as target for chemotherapy
WO2003105758A3 (en) * 2002-06-12 2004-02-26 Avalon Pharmaceuticals Cancer-linked gene as target for chemotherapy
WO2004003564A3 (en) * 2002-06-26 2004-12-29 Europroteome Ag Tumour marker and the use thereof for the diagnosis and treatment of tumour diseases
WO2004003564A2 (en) * 2002-06-26 2004-01-08 Europroteome Ag Tumour marker and the use thereof for the diagnosis and treatment of tumour diseases
US7488803B2 (en) 2002-07-17 2009-02-10 Cambridge Enterprise Limited Antibodies to the extracellular domain of human Fragilis polypeptide and methods of making said antibodies
WO2004007723A3 (en) * 2002-07-17 2004-04-01 Univ Cambridge Tech Genes
WO2004007723A2 (en) * 2002-07-17 2004-01-22 Cambridge University Technical Services Limited Genes
WO2004016784A1 (en) * 2002-08-06 2004-02-26 Genox Research, Inc. Protease inhibitor
US8426571B2 (en) 2002-08-16 2013-04-23 Agensys, Inc. Nucleic acids and corresponding proteins entitled 202P5A5 useful in treatment and detection of cancer
US7696336B2 (en) 2002-08-16 2010-04-13 Agensys, Inc. Nucleic acids and corresponding proteins entitled 251P5G2 useful in treatment and detection of cancer
US8057996B2 (en) 2002-08-16 2011-11-15 Agensys, Inc. Nucleic acids and corresponding proteins entitled 202P5A5 useful in treatment and detection of cancer
US8604169B2 (en) 2002-08-16 2013-12-10 Agensys, Inc. Nucleic acids and corresponding proteins entitled 251P5G2 useful in treatment and detection of cancer
WO2004022778A1 (en) * 2002-09-05 2004-03-18 Garvan Institute Of Medical Research Methods of diagnosis and prognosis of ovarian cancer
EP1557466A4 (en) * 2002-09-27 2006-02-08 Dainippon Sumitomo Pharma Co Tumor antigen protein and utilization thereof
US7700108B2 (en) 2002-09-27 2010-04-20 Dainippon Sumitomo Pharma Co., Ltd. Tumor antigen protein and use thereof
EP2270212A3 (en) * 2002-09-30 2011-06-29 Oncotherapy Science, Inc. Method for diagnosing non-small cell lung cancers
CN1703524B (en) * 2002-09-30 2010-04-07 肿瘤疗法科学股份有限公司 Genes and polypeptides relating to human pancreatic cancer
WO2004031411A3 (en) * 2002-09-30 2004-09-30 Oncotherapy Science Inc Genes and polypeptides relating to human pancreatic cancers
EP2270213A3 (en) * 2002-09-30 2011-06-29 Oncotherapy Science, Inc. Method for diagnosing non-small cell lung cancers
WO2004031411A2 (en) * 2002-09-30 2004-04-15 Oncotherapy Science, Inc. Genes and polypeptides relating to human pancreatic cancers
WO2004031412A3 (en) * 2002-09-30 2004-07-15 Oncotherapy Science Inc Method for diagnosing pancreatic cancer
EP2270501A3 (en) * 2002-09-30 2011-01-19 Oncotherapy Science, Inc. Method for diagnosing non-small cell lung cancers
EP2270219A3 (en) * 2002-09-30 2011-07-27 Oncotherapy Science, Inc. Method for diagnosing non-small cell lung cancers
EP2270217A3 (en) * 2002-09-30 2011-07-27 Oncotherapy Science, Inc. Method for diagnosing non-small cell lung cancers
EP2009117A3 (en) * 2002-09-30 2009-03-18 Oncotherapy Science, Inc. Method for diagnosing pancreatic cancer
WO2004031412A2 (en) * 2002-09-30 2004-04-15 Oncotherapy Science, Inc. Method for diagnosing pancreatic cancer
US7601826B2 (en) 2002-09-30 2009-10-13 Oncotherapy Science, Inc. Genes and polypeptides relating to human pancreatic cancers
US7943730B2 (en) 2002-09-30 2011-05-17 Oncotherapy Science, Inc. Genes and polypeptides relating to human pancreatic cancers
EP2270502A3 (en) * 2002-09-30 2011-01-26 Oncotherapy Science, Inc. Method for diagnosing non-small cell lung cancers
WO2004035082A3 (en) * 2002-10-14 2004-09-23 Develogen Ag Proteins involved in the regulation of energy homeostasis
WO2004038411A3 (en) * 2002-10-24 2004-06-17 Evotec Neurosciences Gmbh Diagnostic and therapeutic use of ensadin-0289 gene and protein for neurodegenerative diseases
US7189524B1 (en) 2002-11-25 2007-03-13 Amgen, Inc. Receptor ligands and methods of modulating receptors
WO2004058969A1 (en) * 2002-12-24 2004-07-15 Takeda Pharmaceutical Company Limited Preventives/remedies for cancer
US7745185B1 (en) 2003-01-21 2010-06-29 Mayo Foundation For Medical Education And Research Sulfotransferase 1A3 sequence variants
US7425624B1 (en) * 2003-01-21 2008-09-16 Mayo Foundation For Medical Education And Research Sulfotransferase 1A3 sequence variants
EP1603514A4 (en) * 2003-01-24 2007-08-22 Bayer Pharmaceuticals Corp Expression profiles for colon cancer and methods of use
EP1603514A2 (en) * 2003-01-24 2005-12-14 Bayer Pharmaceuticals Corporation Expression profiles for colon cancer and methods of use
WO2004070062A3 (en) * 2003-02-04 2004-11-18 Wyeth Corp Compositions and methods for diagnosing and treating cancers
WO2004070062A2 (en) * 2003-02-04 2004-08-19 Wyeth Compositions and methods for diagnosing and treating cancers
WO2004074510A1 (en) * 2003-02-18 2004-09-02 Garvan Institute Of Medical Research Methods of diagnosis and prognosis of pancreatic cancer
EP1599603A1 (en) * 2003-02-18 2005-11-30 Garvan Institute Of Medical Research Methods of diagnosis and prognosis of pancreatic cancer
EP1599603A4 (en) * 2003-02-18 2007-08-22 Garvan Inst Med Res Methods of diagnosis and prognosis of pancreatic cancer
US8609104B2 (en) 2003-02-20 2013-12-17 Seattle Genetics, Inc. Treatment of B-cell cancers with anti-CD70 antibody-drug conjugates
US8535678B2 (en) 2003-02-20 2013-09-17 Seattle Genetics, Inc. Anti-CD70 antibody-drug conjugates and their use for the treatment of cancer and immune disorders
US7662387B2 (en) 2003-02-20 2010-02-16 Seattle Genetics Anti-cd70 antibody-drug conjugates and their use for the treatment of cancer and immune disorders
US8663642B2 (en) 2003-02-20 2014-03-04 Seattle Genetics, Inc. Anti-CD70 antibody-drug conjugates and their use for the treatment and prevention of cancer and immune disorders
WO2004076613A3 (en) * 2003-02-26 2005-01-06 Alexander Herr Human nucleic acid sequences from carcinomas of the bladder
WO2004076613A2 (en) * 2003-02-26 2004-09-10 Alexander Herr Human nucleic acid sequences from carcinomas of the bladder
WO2004079013A1 (en) * 2003-03-03 2004-09-16 Arizona Board Of Regents On Behalf Of The University Of Arizona Ecto-5’-nucleotidase (cd73) used in the diagnosis and the treatment of pancreatic cancer
EP1860186A3 (en) * 2003-03-10 2008-03-12 Japan Science and Technology Corporation Method for distinguishing mesenchymal stem cells using different markers
AU2004201348B2 (en) * 2003-03-31 2008-04-10 Ortho-Clinical Diagnostics, Inc. Colorectal cancer prognostics
JP2004329211A (en) * 2003-03-31 2004-11-25 Veridex Llc Colorectal cancer prognostics
KR101088583B1 (en) * 2003-03-31 2011-12-05 베리덱스 엘엘씨 Colorectal cancer prognostics
EP1526186A2 (en) * 2003-03-31 2005-04-27 Veridex LLC Colorectal cancer prognostics
EP1526186A3 (en) * 2003-03-31 2005-08-17 Veridex LLC Colorectal cancer prognostics
US9382541B2 (en) 2003-04-02 2016-07-05 Nogra Pharma Limited Antisense oligonucleotides (ODN) against SMAD7 and uses thereof in medical field
US8648186B2 (en) 2003-04-02 2014-02-11 Nogra Pharma Limited Antisense oligonucleotides (ODN) against SMAD7 and uses thereof in medical field
US9096854B1 (en) 2003-04-02 2015-08-04 Nogra Pharma Limited Antisense oligonucleotides (ODN) against SMAD7 and uses thereof in medical field
US9279126B2 (en) 2003-04-02 2016-03-08 Nogra Pharma Limited Antisense oligonucleotides (ODN) against SMAD7 and uses thereof in medical field
US8907078B2 (en) 2003-04-02 2014-12-09 Nogra Pharma Limited Antisense oligonucleotides (ODN) against SMAD7 and uses thereof in medical field
US7700757B2 (en) 2003-04-02 2010-04-20 Giuliani Internaitonal Limited Antisense oligonucleotides (ODN) against Smad7 and uses in medical field thereof
US9006418B2 (en) 2003-04-02 2015-04-14 Nogra Pharma Limited Antisense oligonucleotides (ODN) against Smad7 and uses thereof in medical field
US8106182B2 (en) 2003-04-02 2012-01-31 Giuliani International Limited Antisense oligonucleotides (ODN) against Smad7 and uses thereof in medical field
US9518264B2 (en) 2003-04-02 2016-12-13 Nogra Pharma Limited Antisense oligonucleotides (ODN) against SMAD7 and uses thereof in medical field
US10036022B2 (en) 2003-04-02 2018-07-31 Nogra Pharma Limited Antisense oligonucleotides (ODN) against Smad7 and uses thereof in medical field
US9605264B2 (en) 2003-04-02 2017-03-28 Nogra Pharma Limited Antisense oligonucleotides (ODN) against Smad7 and uses thereof in medical field
US7807818B2 (en) 2003-04-02 2010-10-05 Giuliani International Limited Antisense oligonucleotides (ODN) against Smad7 and uses thereof in medical field
US10738309B2 (en) 2003-04-02 2020-08-11 Nogra Pharma Limited Antisense oligonucleotides (ODN) against SMAD7 and uses thereof in medical field
US10633660B2 (en) 2003-04-02 2020-04-28 Nogra Pharma Limited Antisense oligonucleotides (ODN) against SMAD7 and uses thereof in medical field
US9951334B2 (en) 2003-04-02 2018-04-24 Nogra Pharma Limited Antisense oligonucleotides (ODN) against SMAD7 and uses thereof in medical field
WO2004094660A3 (en) * 2003-04-16 2004-12-29 Galderma Res & Dev Use of gene dpysl3 as a marker of psoriasis
FR2853909A1 (en) * 2003-04-16 2004-10-22 Galderma Res & Dev Using polynucleotide probes based on the DPYSL3 gene (Dihydropyrimidinase-like 3), for diagnosis of psoriasis, or predisposition, and in screening for antipsoriatic agents
WO2004094660A2 (en) * 2003-04-16 2004-11-04 Galderma Research & Development, S.N.C. Use of gene dpysl3 as a marker of psoriasis
WO2004104224A2 (en) * 2003-05-21 2004-12-02 F. Hoffmann-La Roche Ag Markers for lxr activation
WO2004104224A3 (en) * 2003-05-21 2005-03-31 Hoffmann La Roche Markers for lxr activation
WO2004111273A3 (en) * 2003-05-30 2005-10-06 Genomic Health Inc Gene expression markers for response to egfr inhibitor drugs
US7604799B2 (en) 2003-06-06 2009-10-20 Medimmune, Llc EphA4 Antibodies
JP2011250795A (en) * 2003-07-17 2011-12-15 Pacific Edge Biotechnology Ltd Marker for detection of gastric cancer
JP2014236737A (en) * 2003-07-17 2014-12-18 パシフィック エッジ バイオテクノロジー リミティド Markers for detection of gastric cancer
JP2007531500A (en) * 2003-07-17 2007-11-08 パシフィック エッジ バイオテクノロジー リミティド Gastric cancer detection marker
EP2325338A3 (en) * 2003-07-17 2011-10-12 Pacific Edge Limited Markers for detection of gastric cancer
AU2004260083B2 (en) * 2003-07-17 2011-04-07 Pacific Edge Limited Markers for detection of gastric cancer
EP2305833A3 (en) * 2003-07-17 2012-02-01 Pacific Edge Limited Markers for detection of gastric cancer
US10179935B2 (en) 2003-07-17 2019-01-15 Pacific Edge Limited Markers for detection of gastric cancer
WO2005013893A2 (en) * 2003-07-24 2005-02-17 Avalon Pharmaceuticals, Inc. Cancer related genes
WO2005013893A3 (en) * 2003-07-24 2006-10-05 Avalon Pharmaceuticals Cancer related genes
EP2311468A1 (en) 2003-08-08 2011-04-20 Perseus Proteomics Inc. Gene overexpressed in cancer
WO2005014818A1 (en) 2003-08-08 2005-02-17 Perseus Proteomics Inc. Gene overexpressed in cancer
AU2004264952B2 (en) * 2003-08-14 2010-12-16 Exelixis, Inc. PRKCs as modifiers of the beta catenin pathway and methods of use
EP1512758A1 (en) * 2003-08-27 2005-03-09 Veridex, LLC Colorectal cancer prognostics
JP2006101701A (en) * 2003-08-28 2006-04-20 Veridex Llc Forecast of prognosis of colorectal cancer
CN1637151A (en) * 2003-08-28 2005-07-13 维里德克斯有限责任公司 Colorectal cancer prognostics
AU2004205270B2 (en) * 2003-08-28 2009-01-22 Veridex, Llc Colorectal cancer prognostics
CN1637151B (en) * 2003-08-28 2013-07-17 维里德克斯有限责任公司 Colorectal cancer prognostics
WO2005024055A1 (en) * 2003-09-05 2005-03-17 Garvan Institute Of Medical Research Methods of diagnosis and prognosis of ovarian cancer ii
WO2005054508A2 (en) * 2003-12-01 2005-06-16 Ipsogen Gene expression profiling of colon cancer by dna microarrays and correlation with survival and histoclinical parameters
WO2005054508A3 (en) * 2003-12-01 2006-05-18 Ipsogen Gene expression profiling of colon cancer by dna microarrays and correlation with survival and histoclinical parameters
EP1694866A4 (en) * 2003-12-12 2007-12-26 Bayer Pharmaceuticals Corp Gene expression profiles and methods of use
EP1694866A2 (en) * 2003-12-12 2006-08-30 Bayer Pharmaceuticals Corporation Gene expression profiles and methods of use
EP1709152A2 (en) * 2003-12-15 2006-10-11 The Regents Of The University Of California Molecular signature of the pten tumor suppressor
AU2004298604B2 (en) * 2003-12-15 2010-09-23 The Regents Of The University Of California Molecular signature of the PTEN tumor suppressor
EP1709152A4 (en) * 2003-12-15 2007-11-07 Univ California Molecular signature of the pten tumor suppressor
WO2005062055A2 (en) * 2003-12-24 2005-07-07 Cancer Research Technology Limited Methods for detecting neoplasia and markers thereof
WO2005062055A3 (en) * 2003-12-24 2005-10-13 Cancer Rec Tech Ltd Methods for detecting neoplasia and markers thereof
US7264841B2 (en) 2004-01-21 2007-09-04 Linda Kalustian Lester Savory gluten-free foods
WO2005076005A2 (en) * 2004-01-30 2005-08-18 Medizinische Universität Wien A method for classifying a tumor cell sample based upon differential expression of at least two genes
WO2005076005A3 (en) * 2004-01-30 2009-02-05 Univ Wien Med A method for classifying a tumor cell sample based upon differential expression of at least two genes
EP2333112A2 (en) 2004-02-20 2011-06-15 Veridex, LLC Breast cancer prognostics
WO2005090603A3 (en) * 2004-03-23 2006-03-02 Oncotherapy Science Inc Method for diagnosing non-small cell lung cancer
US7700573B2 (en) 2004-03-23 2010-04-20 Oncotherapy Science, Inc. Method for diagnosing non-small lung cancer
US7972772B2 (en) 2004-03-23 2011-07-05 Oncotherapy Science, Inc. KIF11 and method for diagnosing non-small cell lung cancer
JP4938451B2 (en) * 2004-03-23 2012-05-23 オンコセラピー・サイエンス株式会社 Methods for diagnosis of non-small cell lung cancer
JP2007530006A (en) * 2004-03-23 2007-11-01 オンコセラピー・サイエンス株式会社 Methods for diagnosis of non-small cell lung cancer
WO2005090991A1 (en) * 2004-03-24 2005-09-29 Oncotherapy Science, Inc. Adam8 as tumor marker and therapeutic target for non-small cell lung cancer
EP1735461A4 (en) * 2004-04-06 2008-10-29 Univ California Orphan receptor tyrosine kinase as a target in breast cancer
JP2007532111A (en) * 2004-04-06 2007-11-15 ザ・レジェンツ・オブ・ザ・ユニバーシティ・オブ・カリフォルニア Orphan receptor tyrosine kinase as a target in breast cancer
EP1735461A1 (en) * 2004-04-06 2006-12-27 The Regents Of The University Of California Orphan receptor tyrosine kinase as a target in breast cancer
WO2005097204A1 (en) * 2004-04-09 2005-10-20 Takeda Pharmaceutical Company Limited Preventives/remedies for cancer
EP2070546A1 (en) 2004-04-09 2009-06-17 Takeda Pharmaceutical Company Limited Preventives/remedies for cancer
US9023605B2 (en) 2004-04-22 2015-05-05 Agensys, Inc. Antibodies and molecules derived therefrom that bind to STEAP-1 proteins
US11401347B2 (en) 2004-04-22 2022-08-02 Agensys, Inc. Antibodies and molecules derived therefrom that bind to STEAP-1 proteins
US8008442B2 (en) 2004-04-22 2011-08-30 Agensys, Inc. Antibodies and molecules derived therefrom that bind to STEAP-1 proteins
US9617346B2 (en) 2004-04-22 2017-04-11 Agensys, Inc. Antibodies and molecules derived therefrom that bind to STEAP-1 proteins
US10597463B2 (en) 2004-04-22 2020-03-24 Agensys, Inc. Antibodies and molecules derived therefrom that bind to STEAP-1 proteins
US7482129B2 (en) * 2004-05-04 2009-01-27 Institute Of Virology, Slovak Academy Of Sciences MN/CA IX/CA9 and Renal Cancer Prognosis
EP2258867A3 (en) * 2004-05-11 2011-04-06 Ganymed Pharmaceuticals AG Identification of surface-associated Antigenes used for the diagnosis and therapy of tumours
US9533043B2 (en) 2004-05-11 2017-01-03 Biontech Ag Identification of surface-associated antigens for tumor diagnosis and therapy
AU2012200098B2 (en) * 2004-05-11 2014-05-08 Ganymed Pharmaceuticals Ag Identification of surface-associated antigens for tumour diagnosis and therapy
AU2014208220B2 (en) * 2004-05-11 2016-08-04 Ganymed Pharmaceuticals Ag Identification of surface-associated antigens for tumor diagnosis and therapy
EP2275571A3 (en) * 2004-05-11 2012-11-21 Ganymed Pharmaceuticals AG Identification of surface-associated Antigenes used for the diagnosis and therapy of tumours
EP2267158A3 (en) * 2004-05-11 2011-04-06 Ganymed Pharmaceuticals AG Identification of surface-associated Antigenes used for the diagnosis and therapy of tumours
US10724103B2 (en) 2004-05-11 2020-07-28 Biontech Ag Identification of surface associated antigen FLJ31461 for tumor diagnosis and therapy
US9255131B2 (en) 2004-05-11 2016-02-09 Ganymed Pharmaceuticals Ag Identification of surface-associated antigens for tumor diagnosis and therapy
EP1774043A2 (en) * 2004-05-28 2007-04-18 Dana-Farber Cancer Institute, Inc. Compositions, kits, and methods for identification, assessment, prevention, and therapy of cancer
EP1774043A4 (en) * 2004-05-28 2009-09-02 Dana Farber Cancer Inst Inc Compositions, kits, and methods for identification, assessment, prevention, and therapy of cancer
US10538816B2 (en) 2004-06-04 2020-01-21 Biotheranostics, Inc. Identification of tumors
US20130023441A1 (en) * 2004-06-04 2013-01-24 Biotheranostics, Inc. Identification of Tumors
US9670553B2 (en) 2004-06-04 2017-06-06 Biotheranostics, Inc. Determining tumor origin
WO2006002433A2 (en) * 2004-06-24 2006-01-05 Veridex, Llc Methods and reagents for the detection of melanoma
WO2006002433A3 (en) * 2004-06-25 2006-08-24 Veridex Llc Methods and reagents for the detection of melanoma
WO2006027693A3 (en) * 2004-09-09 2006-07-06 Exonhit Therapeutics Sa Tumor specific genes and variant RNAS and uses thereof as targets for cancer therapy and diagnosis
WO2006027693A2 (en) * 2004-09-09 2006-03-16 Exonhit Therapeutics Sa Tumor specific genes and variant rnas and uses thereof as targets for cancer therapy and diagnosis
EP1812794A4 (en) * 2004-10-13 2008-09-10 A & G Pharmaceutical Inc Autocrine growth factor receptors and methods
EP1812794A2 (en) * 2004-10-13 2007-08-01 A & G Pharmaceutical, Inc. Autocrine growth factor receptors and methods
US8647624B2 (en) 2004-10-15 2014-02-11 Seattle Genetics, Inc. Treatment of immune disorders with anti-CD70 antibody
US7641903B2 (en) 2004-10-15 2010-01-05 Seattle Genetics, Inc. Anti-CD70 antibody and its use for the treatment and prevention of cancer and immune disorders
US9051372B2 (en) 2004-10-15 2015-06-09 Seattle Genetics, Inc. Anti-CD70 antibody and its use for the treatment of cancer and immune disorders
US7491390B2 (en) 2004-10-15 2009-02-17 Seattle Genetics, Inc. Anti-CD70 antibody and its use for the treatment and prevention of cancer and immune disorders
US8337838B2 (en) 2004-10-15 2012-12-25 Seattle Genetics, Inc. Anti-CD70 antibody and its use for the treatment and prevention of cancer and immune disorders
WO2006053442A1 (en) * 2004-11-22 2006-05-26 Diagnocure Inc. Calml3 a specific and sensitive target for lung cancer diagnosis, prognosis and/or theranosis
WO2006056080A1 (en) * 2004-11-29 2006-06-01 Diagnocure Inc. Gpx2 a specific and sensitive target for lung cancer diagnosis, prognosis and/or theranosis
EP1828237A1 (en) * 2004-12-22 2007-09-05 Kim, Hyun-Kee Human cancer suppressor gene, protein encoded therein, expression vector containing the same, and cell transformed by the vector
EP1828237A4 (en) * 2004-12-22 2008-06-11 Kim Hyun Kee Human cancer suppressor gene, protein encoded therein, expression vector containing the same, and cell transformed by the vector
US8535914B2 (en) * 2005-01-21 2013-09-17 Canon Kabushiki Kaisha Probe, probe set and information acquisition method using the same
EP1871793A4 (en) * 2005-03-30 2009-04-22 Kim Hyun Kee Human protooncogene and protein encoded by same
US8562987B2 (en) 2005-04-19 2013-10-22 Seattle Genetics, Inc. Humanized anti-CD70 binding agents and uses thereof
US9428585B2 (en) 2005-04-19 2016-08-30 Seattle Genetics, Inc. Humanized anti-CD70 binding agents and uses thereof
US9701752B2 (en) 2005-04-19 2017-07-11 Seattle Genetics, Inc. Humanized anti-CD70 binding agents and uses thereof
US8067546B2 (en) 2005-04-19 2011-11-29 Seattle Genetics, Inc. Humanized anti-CD70 binding agents and uses thereof
EP2177614A3 (en) * 2005-05-02 2010-08-11 Toray Industries, Inc. Composition and method for diagnosing esophageal cancer and metastasis of esophageal cancer
US7932032B2 (en) 2005-05-02 2011-04-26 Toray Industries, Inc. Method for diagnosing esophageal cancer
US8198025B2 (en) 2005-05-02 2012-06-12 Toray Industries, Inc. Method for diagnosing esophageal cancer
EP2518166A3 (en) * 2005-05-20 2013-01-09 Veridex, LLC Thyroid fine needle aspiration molecular assay
US11430544B2 (en) 2005-06-03 2022-08-30 Biotheranostics, Inc. Identification of tumors and tissues
US8716021B2 (en) 2005-09-07 2014-05-06 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Use of replicators to prevent gene silencing
WO2007048978A3 (en) * 2005-10-28 2007-09-07 Biomerieux Sa Method for detecting cancer
WO2007048978A2 (en) * 2005-10-28 2007-05-03 Biomerieux Sa Method for detecting cancer
WO2007074341A1 (en) * 2005-12-28 2007-07-05 Randox Laboratories Ltd Detection of oesophageal cancer
WO2008045133A2 (en) * 2006-03-03 2008-04-17 Veridex, Llc Molecular assay to predict recurrence of dukes' b colon cancer
WO2008045133A3 (en) * 2006-03-03 2008-09-12 Veridex Llc Molecular assay to predict recurrence of dukes' b colon cancer
WO2007128984A3 (en) * 2006-04-06 2008-09-25 Randox Lab Ltd Breast cancer makers
WO2007128984A2 (en) * 2006-04-06 2007-11-15 Randox Laboratories Ltd Breast cancer makers
EP2021034A2 (en) * 2006-04-28 2009-02-11 Inis Biotech LLC An isolated dna fragment of the human a33 promoter and its use to control the expression of a heterologous gene in tumor cells
EP2021034A4 (en) * 2006-04-28 2010-04-21 Inis Biotech Llc An isolated dna fragment of the human a33 promoter and its use to control the expression of a heterologous gene in tumor cells
US20100113569A1 (en) * 2006-04-28 2010-05-06 Inis Biotech Llc Isolated dna fragment of the human a33 promoter and its use to control the expression of a heterologous gene in tumor cells
WO2008024009A1 (en) * 2006-08-15 2008-02-28 Institut Molekulyarnoi Genetiki Rossiiskoi Akademii Nauk (Img Ran) Transcriptional level of a timp3 gene in the form of a diagnosis marker of a non-small cell carcinoma of lung
EA010571B1 (en) * 2006-08-15 2008-10-30 Институт Молекулярной Генетики Российской Академии Наук (Имг Ран) Method for diagnosis of non-small cell carcinoma of lung and a kit therefor
EP2052739A1 (en) * 2006-08-16 2009-04-29 Forerunner Pharma Research Co., Ltd. Cancer therapeutic agent comprising ligand for neuromedin u receptor 2 (fm4) molecule as active ingredient
EP2052739A4 (en) * 2006-08-16 2010-01-06 Forerunner Pharma Res Co Ltd Cancer therapeutic agent comprising ligand for neuromedin u receptor 2 (fm4) molecule as active ingredient
US8436147B2 (en) 2006-10-27 2013-05-07 Genentech, Inc. Antibodies and immunoconjugates and uses therefor
US8889847B2 (en) 2006-10-27 2014-11-18 Genentech, Inc. Antibodies and immunoconjugates and uses therefor
US9593167B2 (en) 2006-10-27 2017-03-14 Genentech, Inc. Antibodies and immunoconjugates and uses therefor
US8410069B2 (en) 2007-03-21 2013-04-02 Quark Pharmaceuticals, Inc. Oligoribonucleotide inhibitors of Nrf2 and methods of use thereof for treatment of cancer
WO2008114262A3 (en) * 2007-03-21 2010-02-25 Quark Pharmaceuticals, Inc. Oligoribonucleotide inhibitors of nrf2 and methods of use thereof for treatment of cancer
US7812002B2 (en) 2007-03-21 2010-10-12 Quark Pharmaceuticals, Inc. Oligoribonucleotide inhibitors of NRF2 and methods of use thereof for treatment of cancer
WO2008151110A3 (en) * 2007-06-01 2009-01-22 Univ North Carolina Molecular diagnosis and typing of lung cancer variants
US10196687B2 (en) 2007-06-01 2019-02-05 University Of North Carolina At Chapel Hill Molecular diagnosis and typing of lung cancer variants
WO2008151110A2 (en) * 2007-06-01 2008-12-11 The University Of North Carolina At Chapel Hill Molecular diagnosis and typing of lung cancer variants
US8822153B2 (en) 2007-06-01 2014-09-02 The University Of North Carolina At Chapel Hill Molecular diagnosis and typing of lung cancer variants
WO2008154249A3 (en) * 2007-06-08 2009-07-16 Genentech Inc Gene expression markers of tumor resistance to her2 inhibitor treatment
WO2009021680A1 (en) * 2007-08-14 2009-02-19 F. Hoffmann-La Roche Ag Predictive marker for egfr inhibitor treatment
WO2009052567A1 (en) * 2007-10-23 2009-04-30 Clinical Genomics Pty. Ltd. A method of diagnosing neoplasms - ii
AU2008316313B2 (en) * 2007-10-23 2015-04-16 Clinical Genomics Pty. Ltd. A method of diagnosing neoplasms - II
CN102027128A (en) * 2008-02-11 2011-04-20 哈达斯特医学服务与开发有限公司 Colon cancer associated transcript 1 (CCAT-1) as a cancer marker
WO2009101620A1 (en) * 2008-02-11 2009-08-20 Hadasit Medical Research Services & Development Limited Colon cancer associated transcript 1 (ccat1) as a cancer marker
US9120854B2 (en) 2008-04-11 2015-09-01 Seattle Genetics, Inc. Detection and treatment of pancreatic, ovarian and other cancers
US11319526B2 (en) 2008-05-02 2022-05-03 Seagen Inc. Methods and compositions for making antibodies and antibody derivatives with reduced core fucosylation
US9260499B2 (en) 2008-10-20 2016-02-16 Sapporo Medical University Tumor antigen peptide and use thereof
US8491905B2 (en) 2008-11-26 2013-07-23 Allergan, Inc. KLK-13 antibody inhibitor for treating dry eye
US8211434B2 (en) 2008-11-26 2012-07-03 Allergan, Inc. KLK-13 antibody inhibitor for treating dry eye
US8821874B2 (en) 2008-11-26 2014-09-02 Allergan, Inc. KLK-13 antibody inhibitor for treating dry eye
WO2011009036A1 (en) * 2009-07-16 2011-01-20 Soymeds, Inc. Soybean derived human thyroglobulin, methods of producing and applications thereof
WO2011013729A1 (en) 2009-07-30 2011-02-03 オンコセラピー・サイエンス株式会社 Fused imidazole derivative having ttk inhibitory action
US8637642B2 (en) 2010-09-29 2014-01-28 Seattle Genetics, Inc. Antibody drug conjugates (ADC) that bind to 191P4D12 proteins
US9962454B2 (en) 2010-09-29 2018-05-08 Agensys, Inc. Antibody drug conjugates (ADC) that bind to 191P4D12 proteins
USRE48389E1 (en) 2010-09-29 2021-01-12 Agensys, Inc. Antibody drug conjugates (ADC) that bind to 191P4D12 proteins
US10894090B2 (en) 2010-09-29 2021-01-19 Agensys, Inc. Antibody drug conjugates (ADC) that bind to 191P4D12 proteins
US9314538B2 (en) 2010-09-29 2016-04-19 Agensys, Inc. Nucleic acid molecules encoding antibody drug conjugates (ADC) that bind to 191P4D12 proteins
US9078931B2 (en) 2010-09-29 2015-07-14 Agensys, Inc. Antibody drug conjugates (ADC) that bind to 191P4D12 proteins
US11559582B2 (en) 2010-09-29 2023-01-24 Agensys, Inc. Antibody drug conjugates (ADC) that bind to 191P4D12 proteins
US9498540B2 (en) 2013-03-15 2016-11-22 Novartis Ag Cell proliferation inhibitors and conjugates thereof
WO2016083360A1 (en) * 2014-11-25 2016-06-02 Ait Austrian Institute Of Technology Gmbh Diagnosis of lung cancer
JP2021003136A (en) * 2015-05-15 2021-01-14 国立大学法人高知大学 Pancreatic cancer diagnostic kit
US11180571B2 (en) 2017-04-03 2021-11-23 Hoffmann-La Roche Inc. Antibodies binding to STEAP-1
US11685790B2 (en) 2017-04-03 2023-06-27 Hoffmann-La Roche Inc. Antibodies binding to STEAP-1
US11820827B2 (en) 2019-12-30 2023-11-21 Seagen Inc. Methods of treating myelodysplastic syndrome and acute myeloid leukemia with nonfucosylated anti-CD70 antibodies

Also Published As

Publication number Publication date
AU2001264559A8 (en) 2001-12-17
WO2001094629A3 (en) 2003-09-04
JP2004509612A (en) 2004-04-02
AU2001264559A1 (en) 2001-12-17
CA2411601A1 (en) 2001-12-13
WO2001094629A8 (en) 2002-05-16
EP1358349A2 (en) 2003-11-05

Similar Documents

Publication Publication Date Title
WO2001094629A2 (en) Cancer gene determination and therapeutic screening using signature gene sets
US20080050379A1 (en) Cancer gene determination and therapeutic screening using signature gene sets
EP2444505B1 (en) Urine markers for detection of bladder cancer
US20080305493A1 (en) Determining Cancer-Linked Genes and Therapeutic Targets Using Molecular Cytogenetic Methods
EP2691538A1 (en) Markers associated with cyclin-dependent kinase inhibitors
US20020115057A1 (en) Process for identifying anti-cancer therapeutic agents using cancer gene sets
JP6387001B2 (en) Biomarkers associated with CDK inhibitors
US20040115625A1 (en) Cancer gene determination and therapeutic screening using signature gene sets
EP1980627A1 (en) Method of determining a chemotherapeutic regime and survival expectancy for non small cell lung cancer based on EGFR/CSF-1/CA IX expression
KR101200194B1 (en) Use of SOCS6 as a hepatocellular carcinomar diagnostic marker
US20020165180A1 (en) Process for identifying anti-cancer therapeutic agents using cancer gene sets
US20020102531A1 (en) Cancer gene determination and therapeutic screening using signature gene sets
US20020102532A1 (en) Cancer gene determination and therapeutic screening using signature gene sets
EP1399584A2 (en) Cancer-linked genes as targets for chemotherapy
Aref-Eshghi et al. The oncogenic roles of NTRK fusions and methods of molecular diagnosis
CA2328377A1 (en) A novel method of diagnosing, monitoring, and staging prostate cancer
US20020150877A1 (en) Cancer gene determination and therapeutic screening using signature gene sets
US20030165839A1 (en) Cancer gene determination and therapeutic screening using signature gene sets
US20060134622A1 (en) Amplified cancer target genes useful in diagnosis and thereapeutic screening
US20020110821A1 (en) Cancer gene determination and therapeutic screening using signature gene sets
Spandidos et al. Prognostic significance of oncogenes and tumor suppressor genes in human malignancy
US20020081301A1 (en) Cancer gene determination and therapeutic screening using signature gene sets
AU2017254960B2 (en) Urine markers for detection of bladder cancer
JP2003528630A (en) Human genes and expression products
Wang et al. Differential gene expression profiling in aggressive bladder transitional cell carcinoma compared to the adjacent microscopically normal urothelium by microdissection-SMART cDNA PCR-SSH

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
AK Designated states

Kind code of ref document: C1

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: C1

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

CFP Corrected version of a pamphlet front page
CR1 Correction of entry in section i

Free format text: PAT. BUL. 50/2001 UNDER "PUBLISHED", DELETE "SEQUENCE LISTING PART OF DESCRIPTION PUBLISHED SEPARATELY IN ELECTRONIC FORM AND AVAILABLE UPON REQUEST FROM THE INTERNATIONAL BUREAU."

CFP Corrected version of a pamphlet front page
DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

WWE Wipo information: entry into national phase

Ref document number: 2001938990

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 2411601

Country of ref document: CA

ENP Entry into the national phase in:

Ref country code: JP

Ref document number: 2002 502169

Kind code of ref document: A

Format of ref document f/p: F

WWP Wipo information: published in national office

Ref document number: 2001938990

Country of ref document: EP

WWW Wipo information: withdrawn in national office

Ref document number: 2001938990

Country of ref document: EP